[
  {
    "page": 2,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t2"
  },
  {
    "page": 3,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022"
  },
  {
    "page": 4,
    "source": "table",
    "content": "including a five percent increase in senior management in the U.S. We’ve also initiated several\ncollaborations with external partners and joined key initiatives to ensure we continue to accelerate\nand expand our efforts in this area.\nProtecting the environment and operating sustainably\nIn environmental sustainability, we made progress toward our climate action goals last year and are also\ndeveloping the tools and processes needed to lower our Company's carbon footprint. We’re on track to\nachieve carbon neutrality by 2025, and we're working towards transitioning to renewables to meet our\n2025 renewable energy target as well.\nOperating with the highest standards of ethics and values\nAt Merck, we operate responsibly every day, with an unrelenting commitment to conducting ourselves\naccording to the highest standards. Our code of conduct is at the core of our character, helping us to\nmaintain our reputation as a trustworthy company. To that end, we maintain 100 percent compliance\nto regulatory requirements for active incident monitoring, risk/harm analysis and on-time notification\nof data breaches. We also foster a culture where employees are encouraged to speak up and ensure\nour ethics and values are represented in everything we do.\nAs a signatory to the UN Global Compact, Merck remains committed to improving our communities\nglobally, engaging locally and building sustainability across all our business operations. We continue\nto support environmental protections, human rights, labor protections and anti-corruption efforts\nworldwide. In December 2021, we announced the issuance of our inaugural $1 billion sustainability\nbond, which will support projects and partnerships in our priority ESG areas and contribute to the\nadvancement of the UN Sustainable Development Goals.\nLastly, but certainly not least, I want to thank my Merck colleagues around the world for their\nunwavering dedication and passion for creating and sustaining societal value. And on behalf of Team\nMerck, I want to express my deepest and sincerest appreciation and thanks for your interest, support\nand partnership. We recognize that ESG is not a destination, but instead a journey. While we’re pleased\nwith our progress, we know we have more work to do. We look forward to embracing opportunities,\nwith all our internal and external stakeholders, that enable us to gain momentum, deliver on our\ncommitments and make even greater strides in the years to come.\nVery best regards,\nRob Davis\nChief Executive Officer and President\t\t\t\n\t\t\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\tonomic Environmental Social Indices\t4"
  },
  {
    "page": 5,
    "source": "table",
    "content": "79% of\ncountries\naround the world\nreached with\nour products1\t\t\t\n\t79% of\ncountries\naround the world\nreached with\nour products1\t\t\n\t\t\t\n68,000\nemployees2\t\t\t\n$12.2 billion\nin R&D spend\t\t\t\n\t\t\t\n\t$12.2 billion\nin R&D spend"
  },
  {
    "page": 5,
    "source": "table",
    "content": "68,000\nemployees2"
  },
  {
    "page": 5,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t5"
  },
  {
    "page": 6,
    "source": "table",
    "content": "We operate responsibly every day to enable a safe, sustainable and healthy future for people and communities everywhere\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t6"
  },
  {
    "page": 7,
    "source": "table",
    "content": "Access\nto Health\nIn collaboration with key\nstakeholders, we work to\nensure our science advances\nhealth care, and our products\nare accessible and affordable to\nthose in need.\nTo learn more, see page 14.\t\tEmployees\nWe recognize that our\nability to excel depends on\nthe integrity, knowledge,\nimagination, skill,\ndiversity and wellbeing\nof our employees.\nTo learn more, see page 18.\t\tEnvironmental\nSustainability\nWe consider the impacts of\nour operations and strive\nto operate our business\nsustainably to support the\nhealth of our planet and\nits people.\nTo learn more, see page 21.\t\tEthics\n& Values\nThrough our unwavering\ncommitment to\ntransparency, we earn\nthe trust and confidence\nof our stakeholders.\nTo learn more, see page 23."
  },
  {
    "page": 7,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t7"
  },
  {
    "page": 8,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t8"
  },
  {
    "page": 9,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t9"
  },
  {
    "page": 10,
    "source": "table",
    "content": "Access\nto Health\t\tEmployees\n\t\t\nEnvironmental\nSustainability\t\tEthics\n& Values"
  },
  {
    "page": 10,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t10"
  },
  {
    "page": 11,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t11"
  },
  {
    "page": 12,
    "source": "table",
    "content": "Select awards and recognition\nFortune Disability:IN® 3BL Media\nWorld’s Most Best Places to Work 100 Best Corporate\nAdmired Companies for Disability Inclusion Citizens of 2021 and 2022\n2021 and 2022 2021 and 2022 Ranked #1 in the\nPharmaceuticals, Biotechnology\nRanked #2 most admired 8th year in a row\n& Life Sciences category\ncompany in the Pharmaceutical\ncategory for both years\nJust Capital / Forbes Newsweek Forbes\nJust 100 List 2021 America's Most America’s Best\nand 2022 Responsible Companies Employers 2021\nRanked #1 in the 2021 and 2022 and 2022\nPharmaceuticals & Biotech\nRanked #9 in 2022 8th year in a row\ncategory for both years\nThe Human Rights Bloomberg Barron's\nCampaign Foundation\nGender-Equality 100 Most Sustainable\nBest Places to Work Index 2021 and 2022 Companies 2021\nfor LGBTQ+ Equality 3rd year in a row and 2022\n2021 and 2022 Ranked #1 in the\n9th year in a row Pharmaceuticals category\t\t\nMerck ESG Progress Report 2021/2022\tMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t12"
  },
  {
    "page": 13,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t13"
  },
  {
    "page": 14,
    "source": "table",
    "content": "Diversity in clinical trials\nIn the many countries where we conduct clinical trials, one of our most important\nongoing efforts is to design studies that reflect the diverse populations we serve.\nThis process begins with selection of clinical trial sites in communities serving\nunderrepresented ethnic groups. We plan and conduct our trials in a way that\nincorporates enrollment and other diversity-focused goals, to help drive inclusion\nand access across our programs with our clinical trial sites.\nAdditionally, we continue to be a vocal contributor and participant in various\npartnerships and sponsorships intended to connect with, support and train\nmore U.S.-based clinicians from diverse backgrounds to help drive access\nto clinical research at the community level. This makes our continued work\nas a co-sponsor of the Improving Patient Access to Cancer Clinical Trials\n(IMPACT) study at the Lazarex Cancer Foundation even more important.\nIMPACT is a 3-year pilot study that strives to improve patient enrollment,\nretention, minority participation and equitable access in oncology trials.\nWe’ve also developed and implemented novel tools and approaches intended\nto build relationships and reach potential study participants within their\nown communities, including partnerships with local pharmacies and mobile\nstudy sites."
  },
  {
    "page": 14,
    "source": "table",
    "content": "Access to Health\nGuiding Principles:\n• Discovery • Affordability\nand Invention\n• Strengthening Systems\n• Availability and Addressing Inequity"
  },
  {
    "page": 14,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t14"
  },
  {
    "page": 15,
    "source": "table",
    "content": "Expanded manufacturing capabilities\nfor broad, equitable vaccine access\nMerck’s partnership with UNICEF and Gavi, the Vaccine Alliance to\nbring human papillomavirus (HPV) vaccines to those most in need\nhas been longstanding, with Merck most recently committing to\nprovide 91.5 million doses for use in Gavi-supported countries from\n2021 to 2025. Expansions to our Elkton, Virginia, manufacturing\nfacility were completed in 2022 to increase capacity and supply of\nHPV vaccines following regulatory reviews and approvals. With\nplans for additional expansions to existing and new facilities, we\nexpect supply of HPV vaccines to double between 2020 and 2023.\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 16,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t16"
  },
  {
    "page": 17,
    "source": "table",
    "content": "Merck for Mothers\nMerck for Mothers is our global initiative to help create a world\nwhere no woman has to die while giving life. Applying our business\nand scientific expertise, we are working across sectors to improve\nthe health and wellbeing of women during pregnancy, childbirth\nand postpartum. We’re proud to announce that following the 10th\nanniversary of our initial $500 million investment, we have extended\nthe program with an additional investment of $150 million, with a goal\nof reaching 25 million women by 2025.\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 17,
    "source": "table",
    "content": "Goal\nWe are committed to advancing health equity by reaching\n30 million people in LMICs and in U.S. underserved\npopulations with our social investments, by 2025.3"
  },
  {
    "page": 18,
    "source": "table",
    "content": "Progress towards pay equity\nOur commitment to fair and equitable pay for all employees is\nconsistent with our core values, and we engage external partners\nannually to ensure this commitment is carried out in the U.S.\nand abroad. As of 2021, approximately 75 percent of our global\nemployee population has undergone a pay equity study. We\nanticipate these pay equity studies will achieve nearly global\nworkforce coverage by the end of 2022.\nRead more about our efforts toward pay equity in GRI 405\non page 149.\t\t\n\t\t\t>99% pay equity\nin the U.S. for female and male employees, and\nfor non-white (including Black, Hispanic and\nAsian employees) and white employees, in each\ncase, in equivalent positions\n\t\t\t\n\t\t\t>99% pay equity\nin the U.S. for female and male employees, and\nfor non-white (including Black, Hispanic and\nAsian employees) and white employees, in each\ncase, in equivalent positions"
  },
  {
    "page": 18,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t18"
  },
  {
    "page": 19,
    "source": "table",
    "content": "Expanding our pipeline of diverse talent\nIn the past year, we greatly expanded outreach to Historically Black\nColleges and Universities (HBCUs) by partnering with several\norganizations, including the College Diversity Network and the\nNational Urban League, to focus on building deep partnerships\nwith colleges, students, faculty and alumni of HBCUs.\nWe also focus on systemic barriers that limit the candidate\npool based on geographic location of open positions and talent\nresidency, and on job prerequisites of having prior pharmaceutical\nexperience. To broaden our access to diverse talent, we post some\npositions with an option to work virtually, offer relocation services\nand are agnostic about prior pharmaceutical experience.\nFor more on how our GD&I strategic framework aligns with\nour priorities, see GRI 405 on page 148."
  },
  {
    "page": 19,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t19"
  },
  {
    "page": 20,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t20"
  },
  {
    "page": 21,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t21"
  },
  {
    "page": 22,
    "source": "table",
    "content": "Partnering for progress\nacross our value chain\nIn October 2021, we were one of\n10 pharmaceutical companies to sign on\nto Schneider Electric’s Energize program, a\npioneering collaboration to help pharmaceutical\nand health care suppliers address their own\noperational Scope 2 greenhouse gas emissions\nthrough green power procurement, which in turn\nwill help the signatories reduce their Scope 3\nemissions. We anticipate being able to report\ninitial progress from this endeavor next year.\t\t\t\n\t\t\tProduct stewardship and green and sustainable science\nOur product stewardship program focuses on identifying and either preventing or minimizing potential\nsafety and environmental hazards throughout a product’s life cycle. We are also committed to\nunderstanding, managing and reducing the environmental impacts of our products and the materials\nassociated with discovering and producing them. Our green and sustainable science program uses\na “green-by-design” approach. By using more efficient and innovative processing methods and\ntechnologies, we are reducing the amount of energy, water and raw materials we use to make our\nproducts, thereby minimizing the amount of waste we generate and lowering our production costs.\nFor more information on our product stewardship approach, see our Global Antimicrobial Resistance\nAction Plan, policy on the Responsible Disposal of Medicines and our approach to Pharmaceuticals in\nthe Environment on our corporate website.\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t22"
  },
  {
    "page": 23,
    "source": "table",
    "content": "Our Code of Conduct training series is\nannually completed by more than\n99% of our employees\t\n\t\n\tOur Code of Conduct training series is\nannually completed by more than\n99% of our employees"
  },
  {
    "page": 23,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t23"
  },
  {
    "page": 24,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t24"
  },
  {
    "page": 25,
    "source": "table",
    "content": "References\n1 As defined by the World Bank Country and Lending Groups. Includes only human health products.\n2 As of December 31, 2021.\n3 Social investments include our Company's philanthropic partnerships, programs and impact\ninvestments. Underserved populations are defined as those that face health disparities due to\ndisadvantages related to insurance status, social determinants of health, race, ethnicity, gender\nidentity/sexual orientation, age and/or language preference. The goal is cumulative across the reporting\nperiod of 2021-2025, and is independent of a baseline period.\n4 Third-party reporting is used to calculate the number of people reached through social investments. In\nsome cases, third-party reports may include cumulative people reached for the reporting period, and/or\ndata that is attributable to other partners as well as our Company's philanthropic investment.\n5 Countries are as defined by the World Bank Country and Lending Groups. Includes only human\nhealth products.\n6 100 million total is cumulative. Access strategies, solutions and partnerships include U.S. patient\nassistance programs, voluntary license agreements and partnerships. “Enable more people” is defined\nas implemented and launched in market and is in comparison to the baseline in 2020. “Access” is defined\nas products registered, launched and available in the market. Portfolio of products include Oncology,\nVaccines, HIV treatments and COVID-19 treatments.\n7 Senior management roles reflect Band 700, which comprises our vice presidents and senior\nvice presidents.\n8 The inclusion index is the average favorability score for employees’ responses to three items in the\nemployee Pulse survey (manager supports inclusion, sense of belonging, leaders value perspective)\nacross all surveys in that year.\n9 The employee engagement index is the average favorability score for employees’ responses to items in\nthe employee Pulse survey (happiness, recommend the Company, intent to stay).\n10 Scope 1 emissions are direct greenhouse gas (GHG) emissions that occur from sources that are\ncontrolled or owned by an organization (e.g., emissions associated with fuel combustion in boilers,\nfurnaces or vehicles). Scope 2 emissions are indirect GHG emissions associated with the purchase of\nelectricity, steam, heat or cooling.\n11 We have defined “purchased electricity” as electricity sourced from external suppliers as well as\nrenewable electricity that was generated and utilized on site, where we retained the renewable\nattributes or where we have obtained renewable attributes through contract.\n12 Scope 3 emissions are the result of activities from assets not owned or controlled by the reporting\norganization, but that the organization indirectly impacts in its value chain.\n13 Favorable response indicates the percentage of respondents who respond “yes” to the question stating,\n“I am willing to report employee misconduct and potential ethics or compliance issues.” To align with\nwhere the industry is moving regarding future-oriented ethics and business integrity metrics, this year\nwe have selected a Pulse survey question directly focused on measuring how well Company culture aligns\nwith ethics and integrity principles.\n14 Regulatory requirements differ by region.\n15 Product donations and funding to Ukraine remain on-going in 2022.\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB:"
  },
  {
    "page": 26,
    "source": "table",
    "content": "GRI/SASB\ndisclosures\t\t\t\n\t\t\tGRI/SASB\ndisclosures\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t26"
  },
  {
    "page": 27,
    "source": "table",
    "content": "GRI 102-1\nGRI 102-2\nGRI 102-3\nGRI 102-4\nGRI 102-5\nGRI 102-6\nGRI 102-7\nGRI 102-8\nSASB 000.B"
  },
  {
    "page": 27,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t27"
  },
  {
    "page": 28,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\tGRI/SASB: General disclosures Economic Environmental Social Indices\t28"
  },
  {
    "page": 29,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t29"
  },
  {
    "page": 30,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t30"
  },
  {
    "page": 31,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t31"
  },
  {
    "page": 32,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t32"
  },
  {
    "page": 33,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t33"
  },
  {
    "page": 34,
    "source": "table",
    "content": "Supply chain\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t4\n\t\t\t\t\t137\n\t\t\t\t\t997\n\t\t\t\t\t127\n\t\t\t\t\t10\n\t\t\t\t\t13%\n\t\t\t\t\t1,856\n\t\t\t\t\t$212"
  },
  {
    "page": 34,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t34"
  },
  {
    "page": 35,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t35"
  },
  {
    "page": 36,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tMerck ESG Progress Report 2021/2022\tOve"
  },
  {
    "page": 37,
    "source": "table",
    "content": "CONTINUED: GRI 102-13\nBelow is a list of these U.S. industry and trade groups:\nTrade association dues used for lobbying 2017 2018 2019 2020 2021\nAnimal Health Institute $39,271 $70,687 $70,687 $56,550 $49,481\nBio New Jersey* $4,860 $5,100 $10,140 $8,490 $13,200\nBiotechnology Industry Organization $231,679 $237,468 $274,964 $320,471 $345,716\nCalifornia Life Sciences Association $11,300 $49,980 $49,980 $47,760 $36,740\nCouncil of the Americas* $1,250 $1,250 $1,250 $1,500 $1,500\nChemistry Council of New Jersey $8,775 $8,951 — — $9,000\nHealthcare Distribution Alliance (HDA) — — — — $2,538\nHealthcare Institute of New Jersey $122,100 $114,404 $113,645 $116,983 $147,342\nHealthcare Leadership Council $90,000 $90,000 $90,000 $90,000 $90,000\nLife Sciences Pennsylvania* $4,500 $4,520 $6,360 $4,858 $5,200\nMassachusetts Biotechnology Council $9,884 $10,164 $10,461 $11,055 $11,715\nNational Association for Biomedical Research $20,000 $20,000 $20,000 $20,000 $20,000\nNational Association of Manufacturers $61,792 $56,443 $59,083 $62,132 $80,882\nNew Jersey Chamber of Commerce $4,142 $4,245 $4,374 $3,003 $4,641\nNew Jersey Civil Justice Institute $30,000 $30,000 $30,000 $30,000 $13,500\nPersonalized Medicine Coalition — — — — $3,158\nPharmaceutical Research and Manufacturers of America $11,630,454 $12,548,663 $11,743,028 $18,730,134 $18,146,820\nTexas Healthcare & Bioscience Institute* $5,500 $5,500 $5,500 $5,500 $13,200\nU.S. Chamber of Commerce $206,250 $237,500 $297,000 $130,000 $311,250\nU.S. Council for International Business — $3,445 $3,728 $7,456 —\n*Includes associations where dues are > $25,000. Because the U.S. tax law that requires this reporting does not apply outside the U.S., trade associations that are not subject to this do not provide\nbreakouts of lobbying expenditures from membership dues.\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t37"
  },
  {
    "page": 37,
    "source": "table",
    "content": "Trade association dues used for lobbying\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t$49,481\n\t\t\t\t\t$13,200\n\t\t\t\t\t$345,716\n\t\t\t\t\t$36,740\n\t\t\t\t\t$1,500\n\t\t\t\t\t$9,000\n\t\t\t\t\t$2,538\n\t\t\t\t\t$147,342\n\t\t\t\t\t$90,000\n\t\t\t\t\t$5,200\n\t\t\t\t\t$11,715\n\t\t\t\t\t$20,000\n\t\t\t\t\t$80,882\n\t\t\t\t\t$4,641\n\t\t\t\t\t$13,500\n\t\t\t\t\t$3,158\n\t\t\t\t\t$18,146,820\n\t\t\t\t\t$13,200\n\t\t\t\t\t$311,250\n\t\t\t\t\t—"
  },
  {
    "page": 38,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t38"
  },
  {
    "page": 39,
    "source": "table",
    "content": "GRI 102-16\nGRI 102-17\nSASB 510a.2"
  },
  {
    "page": 39,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t39"
  },
  {
    "page": 40,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022"
  },
  {
    "page": 41,
    "source": "table",
    "content": "GRI 102-18\nGRI 102-19\nGRI 102-20\nGRI 102-21\nGRI 102-22\nGRI 102-23"
  },
  {
    "page": 41,
    "source": "table",
    "content": "Responsible Oversight for ESG topics\nparty\nBoard Provides oversight with respect to the\nCompany’s ESG matters and strategy\nrelated thereto.\nGovernance Monitors and assists the Board in its oversight\nCommittee of our ESG matters, including ensuring that\napplicable ESG matters are subject to review\nby Board committees with relevant areas of\ncompetency, by monitoring and evaluating\nprograms and activities, reviewing strategy\nregarding political engagement and reviewing\nenvironmental sustainability practices.\nCompensation Assists the Board with its oversight of human\n& Management capital management, including our policies and\nDevelopment practices related to talent management, culture,\nCommittee diversity, equity and inclusion. This includes\nmaintaining fair hiring and promotion practices\nand a commitment to sustain pay equity for\nemployees of all genders, races and ethnicities.\nAudit Monitors compliance with the Company’s\nCommittee policies on ethical business practices.\nResearch Monitors compliance with the highest standards\nCommittee of scientific integrity in the conduct of our\nresearch and development.\nManagement Management is responsible for reviewing, refining\nand implementing long-term ESG strategy,\nincluding through its Public Policy & Responsibility\nCouncil comprising diverse cross-functional\nmembers, and for updating the Board and its\ncommittees, as applicable, on ESG matters.\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 41,
    "source": "table",
    "content": "Responsible\nparty\tOversight for ESG topics"
  },
  {
    "page": 42,
    "source": "table",
    "content": "Corporate governance 2017 2018 2019 2020 2021\nIndependent directors on the Board 12 11 12 12 12\nPercent of Board members who are independent 92% 92% 92% 92% 86%\nSeparate chairman of the Board and CEO1 No No No No Yes\nLead independent director Yes Yes Yes Yes Yes\nIndependent audit committee Yes Yes Yes Yes Yes\nIndependent compensation and management development committee Yes Yes Yes Yes Yes\nIndependent governance committee Yes Yes Yes Yes Yes\nWomen on the Board 23% 33% 46% 46% 43%\nMembers of underrepresented ethnic groups on the Board 15% 17% 23% 31% 21%\nNumber of Board meetings scheduled or held2 8 6 6 7 7\nShareholder support of the advisory vote on executive compensation3 95% 93% 92% 91% 92%\nNote: Except as otherwise noted, all figures above are derived from our proxy statement filed the following year and are rounded.\n1 As of July 1, 2021, the positions of Board chairman and CEO are separate.\n2 Refers to number of meetings held in the given calendar year; meetings were held in person and/or via video conference.\n3 Percentages derived from Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission after the applicable annual meeting of shareholders.\t\t\nMerck ESG Progress Report 2021/2022\tMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t42"
  },
  {
    "page": 42,
    "source": "table",
    "content": "Corporate governance\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t12\n\t\t\t\t\t86%\n\t\t\t\t\tYes\n\t\t\t\t\tYes\n\t\t\t\t\tYes\n\t\t\t\t\tYes\n\t\t\t\t\tYes\n\t\t\t\t\t43%\n\t\t\t\t\t21%\n\t\t\t\t\t7\n\t\t\t\t\t92%"
  },
  {
    "page": 43,
    "source": "table",
    "content": "GRI 102-27\nGRI 102-29\nGRI 102-30\nGRI 102-31\nGRI 102-32"
  },
  {
    "page": 43,
    "source": "table",
    "content": "GRI 102-24\nGRI 102-25\nGRI 102-26"
  },
  {
    "page": 43,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t43"
  },
  {
    "page": 44,
    "source": "table",
    "content": "GRI 102-35\nGRI 102-36\nGRI 102-37"
  },
  {
    "page": 44,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t44"
  },
  {
    "page": 45,
    "source": "table",
    "content": "GRI 102-40\nGRI 102-41\nGRI 102-42\nGRI 102-43\nGRI 102-44"
  },
  {
    "page": 45,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t45"
  },
  {
    "page": 46,
    "source": "table",
    "content": "Union membership 2017 2018 2019 2020 2021\nEmployees represented by an independent trade union or covered 29% 30% 30% 30% 23%\nby a collective bargaining agreement (approximate)\t\t\nMerck ESG Progress Report 2021/2022\t\t\t\n\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t46"
  },
  {
    "page": 46,
    "source": "table",
    "content": "Union membership\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t23%"
  },
  {
    "page": 47,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t47"
  },
  {
    "page": 48,
    "source": "table",
    "content": "GRI 102-46\nGRI 102-47"
  },
  {
    "page": 48,
    "source": "table",
    "content": "Our priority ESG topics\nIn our 2021 ESG materiality assessment, the following 10 topics emerged as the most critical for our Company to address, and are grouped below by\nour four ESG focus areas:\n• Access to medicine • Employee health and safety\n(pages 55-74) (pages 131-141)\nAccess\n• Product quality and safety Employees • Employee engagement\nto Health\n(pages 30-34, 55-74, 78-79, a nd diversity\n167-175, Clinical trials page) (pages 29, 45-47, 148-161)\n• Public health risks\n(pages 55-74)\n• C limate change • B usiness ethics • Ethics in R&D\n(pages 53-54, 88-92, 104-109) (pages 39-40, (pages 39-40, 55-74,\nEnvironmental Ethics\n78-79, 174-175, 167-173, Clinical\nSustainability & Values\nCode of Conduct & trials page)\nCompliance)\n• G overnance structures\n• D ata security and mechanisms\nand privacy (pages 39, 41-47,\n(pages 175-177) 132-136, 159-161, 177)\t\t\nMerck ESG Progress Report 2021/2022\tMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t48"
  },
  {
    "page": 48,
    "source": "table",
    "content": "Access\nto Health\t\tEmployees\n\t\t\nEnvironmental\nSustainability\t\tEthics\n& Values"
  },
  {
    "page": 49,
    "source": "table",
    "content": "ESG materiality assessment process\nSector\nExternal\nlandscape\nscore\nreview\nAnalysis ESG material\nand\ntopics\nexternal\nvalidation identified\nInternal\nInternal\nstakeholder\nscore\nsurvey\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t49"
  },
  {
    "page": 50,
    "source": "table",
    "content": "GRI 102-50\nGRI 102-51\nGRI 102-52\nGRI 102-53"
  },
  {
    "page": 50,
    "source": "table",
    "content": "GRI 102-48\nGRI 102-49"
  },
  {
    "page": 50,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t50"
  },
  {
    "page": 51,
    "source": "table",
    "content": "GRI 102-54\nGRI 102-55"
  },
  {
    "page": 51,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t51"
  },
  {
    "page": 52,
    "source": "table",
    "content": "Economic\nSee our GRI index on page 181."
  },
  {
    "page": 52,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t52"
  },
  {
    "page": 53,
    "source": "table",
    "content": "Financial information\t2019\t2020\t2021\n\t\t\t$48.7B\n\t\t\t$12.2B\n\t\t\t68,000\n\t\t\t99,900\n\t\t\t$2.64\n\t\t\t$1.5B"
  },
  {
    "page": 53,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t53"
  },
  {
    "page": 54,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t54"
  },
  {
    "page": 55,
    "source": "table",
    "content": "GRI 203\nSASB 240a.1\nSASB 240a.2\nSASB 240b.2\nSASB 240b.3"
  },
  {
    "page": 55,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t55"
  },
  {
    "page": 56,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t56"
  },
  {
    "page": 57,
    "source": "table",
    "content": "Research and development 2017 2018 2019 2020 2021\nResearch and development expenses (in billions)1,2 $10.3 $9.8 $9.7 $13.4 $12.2\nEmployees involved in research activities (approximate)3 9,800 12,900 13,600 14,800 17,500\nNew Human Health products approved (U.S.)4 4 2 2 1 3\nNew Animal Health products approved (global) 18 14 15 18 16\nProducts in the pipeline and under regulatory review5 26 24 36 39 31\nTop 20 global burdens of diseases addressed by our products and pipeline6,7 88% 88% 100% 88% 71%\nEstablished significant external licenses and collaborations 55 64 78 123 92\n1 R&D expenses include a 2020 $2.7 billion charge related to the acquisition of VelosBio and a 2017 $2.4 billion charge related to the formation of a collaboration with AstraZeneca.\n2 The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements\nthrough the date of the spin-off and therefore are excluded from the 2019, 2020 and 2021 figures presented. Recast figures for 2017 and 2018 are not available.\n3 A change in methodology to ensure greater accuracy, together with a restatement of the Company’s Medical Research Laboratories organization in 2021 resulted in revised numbers of\nemployees from prior years.\n4 Approval of new products only. This does not include approvals for supplemental indications.\n5 Candidates in our Company’s research pipeline or under regulatory review as reported in the Company’s Form 10-K, filed on February 25, 2022. When candidates attain regulatory approval,\nthey are removed from this pipeline view.\n6 As defined by the Institute for Health Metrics and Evaluation (IHME) using GBD 2019 data excluding road injuries, age related hearing loss and neonatal disorders.\n7 This number is lower in 2021 than in 2020 due to spin-off of products to Organon in 2021 in categories of Lower back pain, Headache disorders and Other musculoskeletal.\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t57"
  },
  {
    "page": 57,
    "source": "table",
    "content": "Research and development\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t$12.2\n\t\t\t\t\t17,500\n\t\t\t\t\t3\n\t\t\t\t\t16\n\t\t\t\t\t31\n\t\t\t\t\t71%\n\t\t\t\t\t92"
  },
  {
    "page": 58,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t58"
  },
  {
    "page": 59,
    "source": "table",
    "content": "Availability1 2020 2021\nLogistics partners with security 100% 100%\nrisk assessment completed,\nannually (Target: 100%)\nCountries2 around the world 78% 79%\nreached annually with our\nproducts (Target: 75%)\nOrders shipped on time and in full 98.3% 98.3%\n(Target: 95%)\n1 Reporting on KPIs started with 2020 performance data.\n2 As defined by the World Bank Country and Lending Groups. Includes only human\nhealth products.\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t59"
  },
  {
    "page": 59,
    "source": "table",
    "content": "Availability1\t2020\t2021\n\t\t100%\n\t\t79%\n\t\t98.3%"
  },
  {
    "page": 60,
    "source": "table",
    "content": "We expand access to our products through dedicated,\nmarket-based sustainable access solutions that expand\nthe reach to at-need populations and patients—\nincluding those in LMICs—taking into consideration\npublic health need, economic conditions and health\ncare infrastructure."
  },
  {
    "page": 60,
    "source": "table",
    "content": "Affordability 2019 2020 2021\nNumber of countries where dedicated affordability solutions have been initiated 40 40 NR\nNumber of people reached directly with innovative products through access strategies, NR NR 9.1\nsolutions and partnerships (in millions)*\nPeople reached with sustainable access solutions that enable access to innovative medicines NR NR 57.6\nand vaccines (in millions)*\nPeople reached globally through product donation and patient assistance programs 404 268 197\nand partnerships (estimate in millions)*1,2\nPatents filed in low-income countries, as defined by The World Bank in its country 0 0 0\nand lending groups classifications (annual)*\nNR: Not reported.\n* New key performance indicators (KPI) in this table starting in 2021 to provide more information on the reach of our access strategies, partnerships and solutions to support our Access to\nHealth goals.\n1 Estimate includes product donations through our Company’s Office of Social Business Innovation and patient assistance program.\n2 The significant decrease in people reached in 2020 and 2021 vs 2019 is due to postponed mass drug administration programs as well as shipping delays as a result of the COVID-19 pandemic\nin 2020 and 2021.\t\t\nMerck ESG Progress Report 2021/2022\t\t\t\n\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t60"
  },
  {
    "page": 60,
    "source": "table",
    "content": "Affordability\t2019\t2020\t2021\n\t\t\tNR\n\t\t\t9.1\n\t\t\t57.6\n\t\t\t197\n\t\t\t0"
  },
  {
    "page": 61,
    "source": "table",
    "content": "Patient assistance programs 2017 2018 2019 2020 2021\nPatients utilizing our U.S. Patient Assistance Programs1 244,000 233,000 239,000 189,500 130,002\n30-day prescriptions filled (in millions) 2.1 2.1 2.2 1.6 0.82\n1 Totals represent 2017–2021 volumes of our U.S. Patient Assistance Program. Volumes vary across years based on changes in covered product offerings and changes across the health care\nlandscape. Volumes in 2021 reflect a decline as a result of products transitioned to Organon.\n2 Overall volumes were impacted by products transitioned to Organon.\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t61"
  },
  {
    "page": 61,
    "source": "table",
    "content": "Patient assistance programs\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t130,002\n\t\t\t\t\t0.82"
  },
  {
    "page": 62,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t62"
  },
  {
    "page": 63,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t63"
  },
  {
    "page": 64,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t64"
  },
  {
    "page": 65,
    "source": "table",
    "content": "GARDASIL®\n[Human GARDASIL® 9\nPapillomavirus (Human ROTATEQ® M-M-R®II\nQuadrivalent Papillomavirus (Rotavirus (Measles,\nSelect vaccine (Types 6, 11, 16 9-valent Vaccine, Mumps & VARIVAX® ERVEBO®\nregistrations and and 18) Vaccine, Vaccine, Live, Oral, Rubella Virus (Varicella Virus (Ebola Zaire\nprequalification Recombinant] Recombinant) Pentavalent) Vaccine Live) Vaccine Live) Vaccine, Live)\nProduct is WHO Yes Yes Yes Yes Yes Yes\nprequalified\nDate of prequalification May 20, 2009 February 9, 2018 October 7, 2008 January 6, 2009 February 9, 2018 November 12, 2019\nApproximate number of 130 87 125 77 86 44\ncountries where product\nis registered\n(as of March 2022)\t\t\n\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 65,
    "source": "table",
    "content": "Select vaccine\nregistrations and\nprequalification\tGARDASIL®\n[Human\nPapillomavirus\nQuadrivalent\n(Types 6, 11, 16\nand 18) Vaccine,\nRecombinant]\tGARDASIL® 9\n(Human\nPapillomavirus\n9-valent\nVaccine,\nRecombinant)\tROTATEQ®\n(Rotavirus\nVaccine,\nLive, Oral,\nPentavalent)\tM-M-R®II\n(Measles,\nMumps &\nRubella Virus\nVaccine Live)\tVARIVAX®\n(Varicella Virus\nVaccine Live)\tERVEBO®\n(Ebola Zaire\nVaccine, Live)"
  },
  {
    "page": 66,
    "source": "table",
    "content": "U.S. product portfolio pricing1,2 2017 2018 2019 2020 20216\nList price change (wholesale acquisition cost) vs. prior year3 6.6% 5.5% 4.3% 3.1% 4.4%\nNet price change vs. prior year4 -1.9% 2.99% 1.8% -0.9% 1.7%\nAverage discount5 45.1% 44.3% 43.7% 45.5% 43.5%\nNote: The amount of rebates, discounts and returns is estimated by the Company, and methodologies used may differ from methodologies used by other companies. This data is not audited\nand should be read in conjunction with the Company’s filings with the U.S. Securities and Exchange Commission.\n1 U.S. Product Portfolio includes human health pharmaceutical and vaccine products marketed by the Company, excluding partnered products. The product sales utilized in the analysis\nrepresent ~97 percent of the total U.S. Product Portfolio in 2010 and approached 100 percent of coverage in 2021. 2021 values exclude the impact of LAGEVRIOTM given all revenue was\nthrough the U.S. Emergency Use Authorization (EUA).\n2 Annual percent change vs. prior year was calculated at a product level and weighted across the Company’s U.S. Product Portfolio.\n3 Represents the year-over-year change in the average list price or wholesale acquisition cost (WAC).\n4 Represents the year-over-year change in average net price, which is WAC less rebates, discounts and returns.\n5 Weighted average annual discount is calculated by dividing annual rebates, discounts and returns by annual gross sales.\n6 2021 values exclude the impact of our Organon portfolio; prior year values have not been restated.\t\t\nMerck ESG Progress Report 2021/2022\tMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t66"
  },
  {
    "page": 66,
    "source": "table",
    "content": "U.S. product portfolio pricing1,2\t2017\t2018\t2019\t2020\t20216\n\t\t\t\t\t4.4%\n\t\t\t\t\t1.7%\n\t\t\t\t\t43.5%"
  },
  {
    "page": 67,
    "source": "table",
    "content": "GRI 203-1\nGRI 203-2"
  },
  {
    "page": 67,
    "source": "table",
    "content": "Product registration\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t141\n\t\t\t\t\t7\n\t\t\t\t\t0"
  },
  {
    "page": 67,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t67"
  },
  {
    "page": 68,
    "source": "table",
    "content": "CONTINUED: GRI 203-1 | GRI 203-2\nBelow is a list of products that have been prequalified by WHO as of April 1, 2021.\nProducts prequalified by WHO International Nonproprietary Name (INN) Date of prequalification\nVaccines\nMMR-II® Measles, Mumps, Rubella Virus Vaccine Live January 2009\nROTATEQ® Rotavirus Vaccine, Live, Oral, Pentavalent October 2008\nGARDASIL® Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, May 2009\nRecombinant (including a VVM)\nHuman Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, October 2014\nRecombinant (two-dose regimen to support its programmatic\nfeasibility in developing countries)\nHuman Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, May 2016\nRecombinant (compatibility for use for up to three days in a\ncontrolled temperature chain to facilitate its administration\nin high-temperature, low-cold chain infrastructure areas of\ndeveloping countries)\nGARDASIL®9 Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, February 2018\nRecombinant (including a two-dose-regimen variation)1\nVARIVAX® Varicella Virus Vaccine Live February 2018\n(first varicella vaccine to receive WHO prequalification)\nERVEBO® Ebola Zaire Vaccine, Live November 2019\nHIV/AIDS treatments\nSTOCRIN® Efavirenz (600mg tablet, Oral Solution 30mg) May 2006\nEfavirenz (50mg tablet, 200mg tablet) May 2008\n1 Not currently available through UNICEF procurement; awaiting Vaccine Vial Monitor (VVM).\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t68"
  },
  {
    "page": 68,
    "source": "table",
    "content": "Products prequalified by WHO\tInternational Nonproprietary Name (INN)\tDate of prequalification\nVaccines"
  },
  {
    "page": 69,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t69"
  },
  {
    "page": 70,
    "source": "table",
    "content": "MECTIZAN Donation Program 2017 2018 2019 2020 2021\nDirect financial investment in the program (in millions)1, 2 $3.10 $2.20 $3.10 $2.74 $1.88\nTotal treatments approved (in millions) 300 346 403 417 364\nTreatments approved for river blindness (in millions) 97 111 131 139 105\nTreatments approved for lymphatic filariasis (LF) in river blindness 89 140 141 141 95\nendemic countries (in millions)\nTreatments approved for joint river blindness and LF programs (in millions) 114 83 70.7 75 101\nTreatments approved for lymphatic filariasis (LF) in countries N/A 12 60 62 63\nnot endemic for river blindness2\nRiver blindness endemic countries where elimination of LF 1 1 2 3 3\nhas been validated by the World Health Organization (Target: 30)\nLatin American countries where the elimination of river blindness 4 4 4 4 4\nhas been verified by the World Health Organization (Target: 6)\nN/A: Not available.\n1 Direct investment includes operational support and grants.\n2 F ollowing our Company’s commitment in 2017 to expand the donation of Mectizan to support the implementation of triple-therapy for the elimination of LF in certain settings,\nthe Mectizan Donation Program expanded in 2018 to include donations for LF elimination in countries not endemic for river blindness.\t\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t70"
  },
  {
    "page": 70,
    "source": "table",
    "content": "MECTIZAN Donation Program\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t$1.88\n\t\t\t\t\t364\n\t\t\t\t\t105\n\t\t\t\t\t95\n\t\t\t\t\t101\n\t\t\t\t\t63\n\t\t\t\t\t3\n\t\t\t\t\t4"
  },
  {
    "page": 71,
    "source": "table",
    "content": "Medical Outreach Program (MMOP) 2017 2018 2019 2020 2021\nCountries and territories reached by the MMOP1 62 72 56 46 56\nEstimated number of people reached2,3 376,300 349,570 457,520 283,100 138,900\n1 Distribution of product by country is managed and provided by third party partners who provide the related reporting.\n2 Estimated figures, which assume all product reached patients, are based on converting volume of medicines and vaccines donated. Conversion factors for this estimate were developed using\na combination of QuintilesIMS SMART Data and U.S. product information found on our product website.\n3 Decline in patients reached in 2020 and 2021 primarily due to the decreased availability of certain products offered for donation because they moved to Organon in the 2021 spin-off.\nDisaster relief 2017 2018 2019 2020 2021\nTotal giving value of disaster relief contributions $23.9 $10.2 $16.7 $20.3 $9.0\n(cash and products, in millions)1, 2\n1 Support provided through the Office of Social Business Innovation.\n2 We set the value of our product donations based on the U.S. wholesale acquisition cost.\t\t\t\n\t\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 71,
    "source": "table",
    "content": "Medical Outreach Program (MMOP)\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t56\n\t\t\t\t\t138,900"
  },
  {
    "page": 71,
    "source": "table",
    "content": "Disaster relief\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t$9.0"
  },
  {
    "page": 72,
    "source": "table",
    "content": "Addressing barriers to health\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t99,000\n\t\t\t\t\t$36\n\t\t\t\t\t212\n\t\t\t\t\t$90"
  },
  {
    "page": 72,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t72"
  },
  {
    "page": 73,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t73"
  },
  {
    "page": 74,
    "source": "table",
    "content": "CONTINUED: GRI 203-1 | GRI 203-2\nGrants and contributions 2017 2018 2019 2020 2021\nGrants and contributions (total cash, in-kind and product) $2,722 $2,793 $3,096 $2,988 $1,849\n(estimate in millions)1,2\nCash grants and contributions (estimate in millions) $94 $84 $82 $104 $102\nProduct donations through U.S. Patient Assistance Program $1,112 $1,242 $1,460 $1,603 $1,455\n(in millions)\nProduct donations for ex-U.S. programs and U.S. disaster relief $1,513 $1,464 $1,550 $1,280 $284\n(in millions)2,3\nValuation of employee volunteer time (in-kind, in millions)4,5 $3.2 $3.1 $4.1 $0.9 $3.5\n1 Total contributions for 2021 include approximately $4.9 million for in-kind donations of PPE and other equipment in response to COVID-19 pandemic.\n2 In 2021, we stopped reporting on the market value of donated MECTIZAN, leading in large part to a decrease in our overall reporting of the value of product donations for ex-U.S. programs.\n3 Includes our Medical Outreach Program, the MECTIZAN Donation Program, and MSD division and subsidiary donations.\n4 Includes valuation of volunteer time for only those employees who participated in the MSD Fellowship for Global Health program and our Pro Bono Legal and other skills-based\nvolunteer programs.\n5 2020 decrease in employee volunteering valuation was due to the temporary suspension of the MSD Fellowship for Global Health Program and decreased in-person volunteering as a\nresult of COVID-19.\nPartnership for Giving (P4G) 2017 2018 2019 2020 2021\nTotal contribution (in millions)1, 2 $25 $22 $15.1 $19.3 $18\nNumber of organizations that benefited3 8,770 7,350 5,645 6,468 5,757\nNumber of employee participants4 8,302 6,503 5,083 5,396 5,370\n1 Total contribution includes Foundation matching funds for Dollars for Doers and P4G matching gift programs, and 2021 active-employee participant funds donated through the P4G Direct\nGiving program.\n2 2020 increase is largely due to increase in employee giving and matching gifts to support COVID-19 response efforts.\n3 Includes organizations receiving funds through the P4G matching gift and Dollars for Doers programs.\n4 Includes active employee participants in the P4G matching gift program.\nFor more information on access and pricing, see GRI 203 on page 55.\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t74"
  },
  {
    "page": 74,
    "source": "table",
    "content": "Grants and contributions\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t$1,849\n\t\t\t\t\t$102\n\t\t\t\t\t$1,455\n\t\t\t\t\t$284\n\t\t\t\t\t$3.5"
  },
  {
    "page": 74,
    "source": "table",
    "content": "Partnership for Giving (P4G)\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t$18\n\t\t\t\t\t5,757\n\t\t\t\t\t5,370"
  },
  {
    "page": 75,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview PerfGoRrI/mSASaBn: cGeeneral disclosures Economic Environmental Social Indices\t75"
  },
  {
    "page": 76,
    "source": "table",
    "content": "$2.9 billion\nin spending with diverse\nsuppliers globally"
  },
  {
    "page": 76,
    "source": "table",
    "content": "Supplier diversity (in millions) 2017 2018 2019 2020 2021\nDiverse-supplier spend: Global1 N/A N/A N/A N/A $2,858\nDiverse-supplier spend: U.S. $1,962 $2,111 $2,433 $2,270 $2,374\nSmall-business spend: U.S.2 $802 $973 $979 $775 $1,027\nN/A: Not available.\n1 Starting in 2021, our reports include global spend data.\n2 The acquisition of small suppliers may have impacted their small business status and therefore affected the small business spend reflected above.\t\t\nMerck ESG Progress Report 2021/2022\t\t\t\n\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t76"
  },
  {
    "page": 76,
    "source": "table",
    "content": "Supplier diversity (in millions)\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t$2,858\n\t\t\t\t\t$2,374\n\t\t\t\t\t$1,027"
  },
  {
    "page": 77,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t77"
  },
  {
    "page": 78,
    "source": "table",
    "content": "377,293\nmeals served"
  },
  {
    "page": 78,
    "source": "table",
    "content": "8\nNGOs supported"
  },
  {
    "page": 78,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t78"
  },
  {
    "page": 79,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t79"
  },
  {
    "page": 80,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t80"
  },
  {
    "page": 81,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t81"
  },
  {
    "page": 82,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t\n\t\t\t82"
  },
  {
    "page": 83,
    "source": "table",
    "content": "Environmental\nSee our GRI Index on page 182."
  },
  {
    "page": 83,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t83"
  },
  {
    "page": 84,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t84"
  },
  {
    "page": 85,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t85"
  },
  {
    "page": 86,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t86"
  },
  {
    "page": 87,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 88,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t88"
  },
  {
    "page": 89,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t89"
  },
  {
    "page": 90,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t90"
  },
  {
    "page": 91,
    "source": "table",
    "content": "GRI 302-1\nGRI 302-4"
  },
  {
    "page": 91,
    "source": "table",
    "content": "Total energy use1 2017 2018 2019 2020 2021\nTotal energy use (GJ) 18,402,400 18,274,900 17,710,000 17,182,600 17,224,600\nScope 1 and location-based Scope 2 energy use\n2017 2018 2019 2020 2021\n(% of total)1,2\nNatural gas (Scope 1) 59% 63% 62% 64% 62%\nRenewable energy generated and used on site (Scope 1)3 0.05% 0.06% 0.07% 0.06% 0.06%\nFleet fuel (Scope 1) 13% 10% 9% 7% 8%\nFuel oil (Scope 1) 2% 2% 2% 2% 2%\nBiofuel (Scope 1) 0.7% 0.7% 0.6% 0.7% 0.8%\nSpent solvents (Scope 1) 0% 0% 0% 0% 0%\nCoal (Scope 1) 0% 0% 0% 0% 0%\nPurchased electricity (Scope 2)4,5 22% 21% 23% 23% 24%\nPurchased steam (Scope 2) 3% 3% 3% 3% 3%\nNote: We have defined “purchased electricity” as electricity sourced from external suppliers, as well as renewable electricity that was generated and utilized on site, where we retained the\nrenewable attributes or where we have obtained renewable attributes through contract. GHG figures have been changed from our 2020/2021 report due to a collection methodology update\nsince our last report.\n1 Values are adjusted to reflect the effects of the Organon spin-off on our energy consumption.\n2 May not add to 100 percent due to rounding.\n3 Includes solar, wind and other renewables generated on site, where renewable energy credits or guarantees of origin have been retained or retired.\n4 Reported using Scope 2 location-based value in accordance with the Greenhouse Gas Protocol.\n5 Includes solar, wind and other renewables generated on site, where renewable energy credits (RECs) have been sold.\nERM conducted an independent third-party review of our 2021 GHG and water inventories, and provided limited assurance for the data that we submit to CDP and for inclusion in this report.\nTo view ERM’s limited assurance letter for our environmental data, please visit the ESG Resources page of our corporate website. The verification standard used is ERM CVS’ assurance\nmethodology, which is aligned with the International Standard for Assurance Engagements ISAE 3000 (Revised) and ISO 14064:3 for the verification of GHG emissions.\t\t\n\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 91,
    "source": "table",
    "content": "Total energy use1\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t17,224,600"
  },
  {
    "page": 91,
    "source": "table",
    "content": "Scope 1 and location-based Scope 2 energy use\n(% of total)1,2\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t62%\n\t\t\t\t\t0.06%\n\t\t\t\t\t8%\n\t\t\t\t\t2%\n\t\t\t\t\t0.8%\n\t\t\t\t\t0%\n\t\t\t\t\t0%\n\t\t\t\t\t24%\n\t\t\t\t\t3%"
  },
  {
    "page": 92,
    "source": "table",
    "content": "Scope 1 & market-based Scope 2 energy use (% of total)1,2 2017 2018 2019 2020 2021\nNatural gas (Scope 1) 58% 61% 61% 63% 62%\nRenewable energy generated and used on site, or purchased (Scope 1)3 1% 3% 6% 9% 10%\nFleet fuel (Scope 1) 13% 10% 9% 7% 8%\nFuel oil (Scope 1) 2% 2% 2% 2% 2%\nBiofuel (Scope 1) 0.7% 0.6% 0.6% 0.7% 0.8%\nSpent solvents (Scope 1) 0% 0% 0% 0% 0%\nCoal (Scope 1) 0% 0% 0% 0% 0%\nPurchased electricity (Scope 2)4,5 23% 20% 18% 15% 14%\nPurchased steam (Scope 2) 3% 3% 3% 3% 3%\n1 May not add to 100 percent due to rounding.\n2 Values are adjusted to reflect the effects of the Organon spin-off on our energy consumption.\n3 Includes solar, wind and other renewables generated on site, where renewable energy credits or guarantees of origin have been retained or retired.\n4 Reported using Scope 2 market-based value in accordance with the Greenhouse Gas Protocol.\n5 Includes solar, wind and other renewables generated on site, where renewable energy credits (RECs) have been sold.\nERM conducted an independent third-party review of our 2021 GHG and water inventories, and provided limited assurance for the data that we submit to CDP and for inclusion in this report.\nTo view ERM’s limited assurance letter for our environmental data, please visit the ESG Resources page of our corporate website. The verification standard used is ERM CVS’ assurance\nmethodology, which is aligned with the International Standard for Assurance Engagements ISAE 3000 (Revised) and ISO 14064:3 for the verification of GHG emissions.\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t92"
  },
  {
    "page": 92,
    "source": "table",
    "content": "Scope 1 & market-based Scope 2 energy use (% of total)1,2\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t62%\n\t\t\t\t\t10%\n\t\t\t\t\t8%\n\t\t\t\t\t2%\n\t\t\t\t\t0.8%\n\t\t\t\t\t0%\n\t\t\t\t\t0%\n\t\t\t\t\t14%\n\t\t\t\t\t3%"
  },
  {
    "page": 93,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t93"
  },
  {
    "page": 94,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t94"
  },
  {
    "page": 95,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t95"
  },
  {
    "page": 96,
    "source": "table",
    "content": "Water use by source (million m3)1 2015 2016 2017 2018 2019 2020 2021\nGroundwater 12.0 10.2 10.0 10.3 10.2 10.1 9.7\nPurchased water 7.1 6.5 6.1 7.2 6.9 7.0 7.1\nSurface water 3.9 3.1 2.7 2.3 2.6 2.9 2.6\nTotal2 23.0 19.8 18.8 19.9 19.7 20.0 19.4\nERM conducted an independent third-party review of our 2021 GHG and water inventories, and provided limited assurance for the data that we submit to CDP and for inclusion in this report.\nTo view ERM’s limited assurance letter for our environmental data, please visit the ESG Resources page of our corporate website. The verification standard used is ERM CVS’ assurance\nmethodology, which is aligned with the International Standard for Assurance Engagements ISAE 3000 (Revised) and ISO 14064:3 for the verification of GHG emissions.\n1 In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired and sold. For example, prior-year data in this table\nhas been adjusted to remove facilities that were spun-off as part of the Organon spin-off. Adjustments also reflect changes in methodology to ensure consistency from year to year.\n2 All values above are rounded to one decimal place. As a result, the total values shown may not equal the sum of the individual source totals.\t\t\nMerck ESG Progress Report 2021/2022\t\t\t\n\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t96"
  },
  {
    "page": 96,
    "source": "table",
    "content": "Water use by source (million m3)1\t2015\t2016\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t\t\t9.7\n\t\t\t\t\t\t\t7.1\n\t\t\t\t\t\t\t2.6\n\t\t\t\t\t\t\t19.4"
  },
  {
    "page": 97,
    "source": "table",
    "content": "CONTINUED: GRI 303-3\nWater use by risk in the following tables is categorized according to data obtained via the WRI Aqueduct Water Risk Atlas tool\nand our internal risk assessment.\nNorth America\n79%\nEurope, Middle East and Africa\n13%\nRisk breakdown\nExtremely high (0.21%)\nAsia Pacific\nHigh (13.94%)\n6%\nMed to high (14.49%)\nLatin America\nLow to med (42.80%)\n2% Low (14.30%)\nWater use and risk by\nregion (million m3)—\nWRI Aqueduct Risk Extremely Med to Low to % of\nTool output (2021) high High high med Low N/A Total Total\nNorth America 0.00 2.18 2.90 7.88 0.23 2.08 79% 15.27\nEurope, Middle East 0.03 0.41 0.02 0.41 1.40 0.20 13% 2.48\nand Africa\nAsia Pacific 0.01 0.00 0.08 0.00 0.94 0.21 6% 1.24\nLatin America 0.00 0.11 0.00 0.00 0.20 0.07 2% 0.38\nTotal1 0.04 2.70 3.00 8.29 2.77 2.57 100% 19.37\nN/A: Not available.\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\t\t\n\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 97,
    "source": "table",
    "content": "Water use and risk by\nregion (million m3)—\nWRI Aqueduct Risk\nTool output (2021)\tExtremely\nhigh\tHigh\tMed to\nhigh\tLow to\nmed\tLow\tN/A\t% of\nTotal\tTotal\n\t\t\t\t\t\t\t\t15.27\n\t\t\t\t\t\t\t\t2.48\n\t\t\t\t\t\t\t\t1.24\n\t\t\t\t\t\t\t\t0.38\n\t\t\t\t\t\t\t\t19.37"
  },
  {
    "page": 98,
    "source": "table",
    "content": "CONTINUED: GRI 303-3\nWater use in areas of high to extremely\nhigh water risk by region (million m3)— Purchased\nWRI Aqueduct Risk Tool output (2021) Groundwater Surface water water Total\nNorth America 0.32 0.00 1.86 2.18\nEurope, Middle East and Africa 0.03 0.00 0.41 0.44\nLatin America 0.00 0.00 0.01 0.01\nAsia Pacific 0.03 0.00 0.08 0.11\nTotal1 0.39 0.00 2.36 2.75\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\nWater use in areas of high to\nextremely high water risk by region\n(million m3)—after internal risk Purchased\nassessment methodology (2021) Groundwater Surface water water Total\nNorth America 0.00 0.00 0.00 0.00\nEurope, Middle East and Africa 0.03 0.00 0.04 0.07\nLatin America 0.00 0.00 0.64 0.64\nAsia Pacific 0.03 0.00 0.08 0.11\nTotal1 0.07 0.00 0.75 0.82\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\nFor information on our water risk assessment approach, please see GRI 303-1 on page 95.\t\t\nMerck ESG Progress Report 2021/2022\t\t\t\n\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t98"
  },
  {
    "page": 98,
    "source": "table",
    "content": "Water use in areas of high to extremely\nhigh water risk by region (million m3)—\nWRI Aqueduct Risk Tool output (2021)\tGroundwater\tSurface water\tPurchased\nwater\tTotal\n\t\t\t\t2.18\n\t\t\t\t0.44\n\t\t\t\t0.01\n\t\t\t\t0.11\n\t\t\t\t2.75"
  },
  {
    "page": 98,
    "source": "table",
    "content": "Water use in areas of high to\nextremely high water risk by region\n(million m3)—after internal risk\nassessment methodology (2021)\tGroundwater\tSurface water\tPurchased\nwater\tTotal\n\t\t\t\t0.00\n\t\t\t\t0.07\n\t\t\t\t0.64\n\t\t\t\t0.11\n\t\t\t\t0.82"
  },
  {
    "page": 99,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t99"
  },
  {
    "page": 100,
    "source": "table",
    "content": "Total water discharge External treatment\nby region (million m3) (2021) Surface water facilities Total1 % of total\nNorth America 9.86 3.82 13.68 80%\nEurope, Middle East and Africa 1.03 1.28 2.31 13%\nAsia Pacific 0.04 0.79 0.84 5%\nLatin America 0.00 0.28 0.28 2%\nTotal1 10.93 6.17 17.11 100%\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\nWater discharge in areas of high to\nextremely high water risk, by region\n(million m3)—WRI Aqueduct Risk External treatment\nAssessment output (2021) Surface water facilities Total\nNorth America 0.53 1.64 2.17\nEurope, Middle East and Africa 0.02 0.36 0.38\nAsia Pacific 0.00 0.01 0.01\nLatin America 0.00 0.10 0.10\nTotal1 0.55 2.11 2.66\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\t\t\nMerck ESG Progress Report 2021/2022\t\t\t\n\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t100"
  },
  {
    "page": 100,
    "source": "table",
    "content": "Total water discharge\nby region (million m3) (2021)\tSurface water\tExternal treatment\nfacilities\tTotal1\t% of total\n\t\t\t\t80%\n\t\t\t\t13%\n\t\t\t\t5%\n\t\t\t\t2%\n\t\t\t\t100%"
  },
  {
    "page": 100,
    "source": "table",
    "content": "Water discharge in areas of high to\nextremely high water risk, by region\n(million m3)—WRI Aqueduct Risk\nAssessment output (2021)\tSurface water\tExternal treatment\nfacilities\tTotal\n\t\t\t2.17\n\t\t\t0.38\n\t\t\t0.01\n\t\t\t0.10\n\t\t\t2.66"
  },
  {
    "page": 101,
    "source": "table",
    "content": "Water discharge in areas of high to extremely\nhigh water risk, by region (million m3)—after\ninternal risk assessment methodology (2021)\tSurface water\tExternal\ntreatment\nfacilities\tTotal\n\t\t\t0.00\n\t\t\t0.05\n\t\t\t0.40\n\t\t\t0.10\n\t\t\t0.54"
  },
  {
    "page": 101,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t101"
  },
  {
    "page": 102,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t102"
  },
  {
    "page": 103,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t103"
  },
  {
    "page": 104,
    "source": "table",
    "content": "GHG emissions goals\nGoal\nReduce our operational greenhouse gas (GHG) emissions\n(i.e., Scopes 1 & 2) 46% by 2030 from a 2019 baseline.\nProgress:\n9% reduction in Scope 1 and 2 emissions from 2019 baseline.\nGoal\nReduce our value chain (Scope 3) GHG emissions by 30%\nby 2030 from a 2019 baseline.\nProgress:\n9% increase in Scope 3 emissions from 2019 baseline.\nGoal\nAchieve carbon neutrality across our operations by 2025\n(Scopes 1 & 2 emissions).\nProgress:\nIn progress. Any remaining emissions will be offset with high-quality\noffsets in 2025.\nRenewable energy goal\nGoal\nSource 100% of our purchased electricity from\nrenewables by 2025.\nProgress:\n41% of purchased electricity sourced from renewables in 2021.\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t\n\t\t\t104"
  },
  {
    "page": 105,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t105"
  },
  {
    "page": 106,
    "source": "table",
    "content": "GRI 305-1\nGRI 305-2\nGRI 305-3\nGRI 305-4\nGRI 305-5"
  },
  {
    "page": 106,
    "source": "table",
    "content": "Total GHGs (MT CO e)1 2017 2018 2019 2020 2021\n2\nScope 11,3, 5 777,400 768,900 732,900 715,000 695,700\nScope 2 location-based1,3, 5 420,300 398,600 381,900 367,000 374,200\nScope 2 market-based1,3, 5 438,100 363,300 285,900 227,800 230,000\nTotal GHGs (Scope 1 & 2 market-based)1,3 1,215,500 1,132,200 1,018,800 942,800 925,700\nScope 3 GHGs1,3 5,940,500 5,668,400 6,380,500 6,457,800 6,958,900\nGHG intensity2,4 19.73 18.38 16.02 14.16 13.61\n1 In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired, sold or spun-off. Adjustments also reflect changes in\nmethodology to ensure consistency from year to year, including Scope 2 emission factor updates [E-GRID (2021), IEA (2021), EU Residual (2021), UK Defra (2021) & Inventarios Corporativos\n(2021)] and Scope 1 & 3 emission factor updates [EPA Climate Leaders (2021)].\n2 Total Scope 1 & Scope 2 market-based metric tons COe per employee.\n2\n3 Values are adjusted to reflect the effects of the Organon spin-off on our emissions.\n4 Adjusted to remove employees transferred to Organon in connection with the spin-off.\n5 The operational control approach is used to account for GHG emissions for Company facilities globally. Only those facilities over which Merck has operational control are included in the\nGHG inventory.\nERM conducted an independent third-party review of our 2021 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for inclusion\nin this report. To view ERM’s limited assurance letter for our environmental data, please visit the ESG Resources page of our corporate website. The verification standard used is ERM CVS’\nassurance methodology, which is aligned with the International Standard for Assurance Engagements ISAE 3000 (Revised) and ISO 14064:3 for the verification of GHG emissions.\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t106"
  },
  {
    "page": 106,
    "source": "table",
    "content": "Total GHGs (MT CO e)1\n2\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t695,700\n\t\t\t\t\t374,200\n\t\t\t\t\t230,000\n\t\t\t\t\t925,700\n\t\t\t\t\t6,958,900\n\t\t\t\t\t13.61"
  },
  {
    "page": 107,
    "source": "table",
    "content": "CONTINUED: GRI 305-1 | GRI 305-2 | GRI 305-3 | GRI 305-4 | GRI 305-5\nScope 3 GHG details (MT CO e) 2017 2018 2019 2020 2021\n2\nPurchased goods and services1,2 4,671,300 4,295,500 4,827,900 5,050,900 5,465,800\nCapital goods1,2 186,700 221,800 329,000 455,100 453,200\nGHG emissions from fuel and energy-related activities 250,600 232,100 220,200 194,100 216,500\nnot included in Scopes 1 & 22,3\nUpstream transportation and distribution1,2 236,400 242,600 240,000 232,800 237,800\nWaste generated in operations (excluding recycled and 16,400 17,700 18,800 21,900 23,800\ncomposted waste)2,4,5\nGHG emissions related to employee business travel2,6,7 209,800 289,400 327,200 208,600 241,100\nEmployee commuting2,8 213,400 213,400 243,700 114,800 117,200\nDownstream transportation and distribution2,9 114,200 113,200 124,800 136,000 155,200\nGHG emissions from use of sold products2,10 2200 600 600 600 700\nEnd-of-life treatment of sold products2,11 39,500 42,100 48,300 43,000 47,600\nTotal2,12 5,940,500 5,668,400 6,380,500 6,457,800 6,958,900\nLimited Data Assurance was granted for 22,652 or 9% emissions calculated from primary travel vendor data and employee reimbursable travel mileage data. The total reported here includes\nnon-primary travel vendor data emissions, which were based on our 2021 third-party spend data and an Economic Input-Output Model performed by Climate Earth, Inc.\n1 Based on third-party spend data and an Economic Input-Output Model performed by Climate Earth, Inc.\n2 Values are adjusted to reflect the effects of the Organon spin-off on our emissions.\n3 Emission factors from Argonne National Laboratory's GREET Model (https://greet.es.anl.gov/) were used in conjunction with primary fuel and energy-use data.\n4 Primary-waste data were used with the U.S. EPA’s WARM Model (https://www.epa.gov/warm).\n5 Including recycled and composted waste in these calculations would result in negative emissions in 2017 (-41,200 MT CO₂e), 2018 (-43,700 MT CO₂e), 2019 (-62,400 MT CO₂e), 2020\n(-48,900 MT CO₂e) and 2021 (-46,300 MT CO₂e).\n6 Based on primary travel vendor data, employee-reimbursable mileage and UK Defra factors.\n7 Emissions are based on primary vendor data where available and economic input-output modeling performed by Climate Earth, Inc., using spend data.\n8 2020 and 2021 reductions caused by shifts to remote working due to the COVID-19 pandemic.\n9 Emissions were calculated using our “Upstream transportation and distribution” spend data as a worst-case estimate entered into the WRI Quantis tool. We assumed that all “downstream”\nmaterial would first have been stored, transported and handled “upstream.”\n10 Due to recent acquisitions, we are currently evaluating the applicability of additional products to this category. This category currently includes the impacts of our Animal Health products\nENGEMYCIN® (oxytetracycline), NEO SPRAY CAF® (oxytetracyclinum), OXYTETRIN® LA (oxytetracycline) only.\n11 Calculated assuming that all primary, secondary and tertiary packaging purchased was disposed of by our customers. Packaging material data was used with the U.S. EPA’s WARM Model.\n12 May not add up to total due to rounding.\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t107"
  },
  {
    "page": 107,
    "source": "table",
    "content": "Scope 3 GHG details (MT CO e)\n2\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t5,465,800\n\t\t\t\t\t453,200\n\t\t\t\t\t216,500\n\t\t\t\t\t237,800\n\t\t\t\t\t23,800\n\t\t\t\t\t241,100\n\t\t\t\t\t117,200\n\t\t\t\t\t155,200\n\t\t\t\t\t700\n\t\t\t\t\t47,600\n\t\t\t\t\t6,958,900"
  },
  {
    "page": 108,
    "source": "table",
    "content": "GRI 305-6\nGRI 305-7"
  },
  {
    "page": 108,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t108"
  },
  {
    "page": 109,
    "source": "table",
    "content": "Air pollutant emissions (MT)1 2017 2018 2019 2020 2021\nNitrogen oxides (NOx) 458 470 369 367 348\nSulfur oxides (SOx) 36 29 26 22 25\nVolatile organic compounds (VOCs) 354 382 368 356 310\nOzone-depleting substances (ODS) 0.1 0.3 0.6 0.3 0.3\nNote: Previously reported data have been restated per our methodology, which includes adding facilities that have been acquired and removing facilities that have been sold as operating sites\nor spun-off.\n1 Data are estimated using conservative assumptions and factors, not measured or weighed.\t\t\n\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 109,
    "source": "table",
    "content": "Air pollutant emissions (MT)1\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t348\n\t\t\t\t\t25\n\t\t\t\t\t310\n\t\t\t\t\t0.3"
  },
  {
    "page": 110,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\tGRI/SASB: General disclosures Economic Environmental Social Indices\t110"
  },
  {
    "page": 111,
    "source": "table",
    "content": "GRI 306-1\nGRI 306-2"
  },
  {
    "page": 111,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 112,
    "source": "table",
    "content": "Waste management goals\nGoal\nBy 2025, no more than 20% of our global operational\nwaste will be sent to landfills and incinerators\n(without energy recovery).\nProgress:\nIn 2021, 33% of operational waste was sent to landfill\nand incinerators (without energy recovery).\nGoal\nBy 2025, at least 50% of our sites will send zero\nwaste to landfills.\nProgress:\nIn 2021, 52% of sites sent zero waste to landfill.\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\tGRI/SASB: General disclosures Economic Environmental Social Indices\t112"
  },
  {
    "page": 113,
    "source": "table",
    "content": "GRI 306-3\nGRI 306-4\nGRI 306-5\nSASB 250a.4"
  },
  {
    "page": 113,
    "source": "table",
    "content": "Global operational waste (% of total) 2017 2018 2019 2020 2021\nIncinerated (without energy recovery) 19% 24% 19% 23% 28%\nLandfilled 10% 9% 7% 5% 5%\nTotal (2025 Goal <20%) 29% 33% 26% 28% 33%\nHazardous waste (MT) 2017 2018 2019 2020 2021\nIncinerated (without energy recovery)1 13,462 17,639 14,025 16,649 22,086\nEnergy recovery 9,538 10,300 13,655 15,330 14,029\nRecycled 7,979 6,827 8,034 8,685 9,824\nOther 2,423 2,221 1,865 1,662 2,824\nReused 1,505 695 1,147 480 1,510\nLandfilled 745 731 938 198 315\nComposted 0 0 0 0 0\nTotal 35,652 38,413 39,674 43,004 50,588\nNote: Data from the Animal Health Intelligence facilities, which were acquired in 2019 and thereafter, are not included in the figures above. These metrics will be reported in the future as\nthese sites become fully integrated into the Company internal reporting processes.\n1 A data collection error was discovered at one of our sites in 2021 that resulted in the amount of hazardous waste being sent for incineration (without energy recovery) to be underreported\nby that site. The data collection process was revised in 2021 to correct this. As a result, the reported values for Hazardous Waste Incinerated (without energy recovery) show an increase\nfrom the values reported in 2020. This is primarily due to this error and is not an actual increase in the quantity of waste sent for incineration (without energy recovery).\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t113"
  },
  {
    "page": 113,
    "source": "table",
    "content": "Global operational waste (% of total)\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t28%\n\t\t\t\t\t5%\n\t\t\t\t\t33%"
  },
  {
    "page": 113,
    "source": "table",
    "content": "Hazardous waste (MT)\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t22,086\n\t\t\t\t\t14,029\n\t\t\t\t\t9,824\n\t\t\t\t\t2,824\n\t\t\t\t\t1,510\n\t\t\t\t\t315\n\t\t\t\t\t0\n\t\t\t\t\t50,588"
  },
  {
    "page": 114,
    "source": "table",
    "content": "Non-hazardous waste (MT) 2017 2018 2019 2020 2021\nRecycled 15,188 12,975 14,188 13,537 13,073\nEnergy recovery 8,576 9,273 10,030 8,280 7,066\nComposted 4,668 4,798 4,843 4,892 5,872\nLandfilled 6,633 5,684 4,603 4,061 3,702\nOther 212 209 1,025 1,717 266\nReused 1,071 2,204 660 963 583\nIncinerated (without energy recovery) 426 374 477 1,124 850\nTotal 36,774 35,517 35,826 34,574 31,412\nNote: Data from the Animal Health Intelligence facilities, which were acquired in 2019 and thereafter, are not included in the figures above. These metrics will be reported in the future as\nthese sites become fully integrated into the Company internal reporting processes.\t\t\t\nMerck ESG Progress Report 2021/2022\t\t\t\t\n\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t114"
  },
  {
    "page": 114,
    "source": "table",
    "content": "Non-hazardous waste (MT)\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t13,073\n\t\t\t\t\t7,066\n\t\t\t\t\t5,872\n\t\t\t\t\t3,702\n\t\t\t\t\t266\n\t\t\t\t\t583\n\t\t\t\t\t850\n\t\t\t\t\t31,412"
  },
  {
    "page": 115,
    "source": "table",
    "content": "Total waste (MT) 2017 2018 2019 2020 2021\nRecycled 23,167 19,802 22,222 22,222 22,897\nEnergy recovery 18,114 19,573 23,685 23,610 21,095\nComposted 4,668 4,798 4,843 4,892 5,872\nLandfilled 7,378 6,415 5,541 4,259 4,017\nOther 2,635 2,430 2,890 3,379 3,090\nReused 2,576 2,899 1,807 1,443 2,093\nIncinerated (without energy recovery)1 13,888 18,013 14,512 17,773 22,936\nTotal 72,426 73,930 75,500 77,578 82,000\nNote: Data from the Animal Health Intelligence facilities, which were acquired in 2019 and thereafter, are not included in the figures above. These metrics will be reported in the future as\nthese sites become fully integrated into the Company internal reporting processes.\n1 A data collection error was discovered at one of our sites in 2021 that resulted in the amount of hazardous waste being sent for incineration (without energy recovery) to be underreported by\nthat site. The data collection process was revised in 2021 to correct this. As a result, the reported values for Hazardous Waste Incinerated (without energy recovery) show an increase from\nthe values reported in 2020. This is primarily due to this error and is not an actual increase in the quantity of waste sent for incineration (without energy recovery).\t\t\t\n\tMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t115"
  },
  {
    "page": 115,
    "source": "table",
    "content": "Total waste (MT)\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t22,897\n\t\t\t\t\t21,095\n\t\t\t\t\t5,872\n\t\t\t\t\t4,017\n\t\t\t\t\t3,090\n\t\t\t\t\t2,093\n\t\t\t\t\t22,936\n\t\t\t\t\t82,000"
  },
  {
    "page": 116,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t116"
  },
  {
    "page": 117,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t117"
  },
  {
    "page": 118,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t118"
  },
  {
    "page": 119,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t119"
  },
  {
    "page": 120,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t120"
  },
  {
    "page": 121,
    "source": "table",
    "content": "Notices of violations (NOVs)\nand citations 2017 2018 2019 2020 2021\nEnvironmental 5 6 9 9 16\nSafety 3 1 4 3 2\nFines 2017 2018 2019 2020 2021\nEnvironmental fines paid $0 $0 $17,690 $21,022 $191,870\nNumber of environmental fines 0 0 3 3 4\nSafety fines paid $0 $0 $0 $0 $736\nNumber of safety fines 0 0 0 0 1\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t121"
  },
  {
    "page": 121,
    "source": "table",
    "content": "Notices of violations (NOVs)\nand citations\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t16\n\t\t\t\t\t2"
  },
  {
    "page": 121,
    "source": "table",
    "content": "Fines\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t$191,870\n\t\t\t\t\t4\n\t\t\t\t\t$736\n\t\t\t\t\t1"
  },
  {
    "page": 122,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t122"
  },
  {
    "page": 123,
    "source": "table",
    "content": "External\nmanufacturing\nEHS assessments\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t42\n\t\t\t\t\t54\n\t\t\t\t\t96"
  },
  {
    "page": 123,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t123"
  },
  {
    "page": 124,
    "source": "table",
    "content": "Social\nSee our GRI index on page 183."
  },
  {
    "page": 124,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t124"
  },
  {
    "page": 125,
    "source": "table",
    "content": "GRI 401-1\nSASB 330a.1\nSASB 330a.2"
  },
  {
    "page": 125,
    "source": "table",
    "content": "Turnover Overall Voluntary Turnover\n(global) 2017 2018 2019 2020 2021 Turnover by turnover turnover distribution\ndivision (2021) rate 1 rate by gender and\nOverall\n10.7% 11.8% 9.9% 8.5% 11.1% region (2021) Female Male\nturnover rate1 Animal Health 8.4% 6.2%\nVoluntary Overall 48% 52%\n6.5% 6.8% 6.9% 6.0% 8.8% Communication 8.4% 7.9%\nturnover rate\nand Policy Asia Pacific 49% 51%\n1 I ncludes all types of turnover of regular employees. Regular employees\nare defined as employees who do not have a predetermined end date Corp Compliance 4.4% 4.4% EEMEA 50% 50%\nto employment.\nGlobal Services 9.8% 8.2% Latin America 48% 52%\nOverall Voluntary Global Human Health 16.2% 12.6% Europe 45% 55%\nTurnover by turnover turnover Human Resources 13.9% 9.5% Japan 42% 58%\nregion (2021) rate 1 rate\nLegal, Security, 8.3% 6.9% U.S. 47% 53%\nAsia Pacific 12.6% 10.3% Safety &\nChina 52% 48%\nEnvironment\nLatin America 11.3% 5.7%\nCanada 54% 46%\nEEMEA (Eastern Manufacturing 8.7% 6.1%\nEurope, Middle 15.5% 9.4% Division Notes: Data above includes all types of turnover of regular employees.\nEast and Africa) Regular employees are defined as employees who do not have a\nResearch 9.6% 8.9% predetermined end date to employment. To align with U.S. government\nreporting requirements, the ESG data for gender diversity in this\nJapan 3.1% 2.6% Laboratories\nreport uses the terms men and women. We recognize and embrace the\ngender spectrum and diversity in our employees, and have internally\nEurope 8.6% 5.4% Population Health & 9.2% 7.4% established voluntary Self-ID options for employees to self-report\non their gender identity. The totals in this report may not equal 100\nU.S. 8.7% 8.0% Sustainability percent due to rounding or employees who have not reported their\ngender and/or race/ethnicity.\nChina 29.2% 25.0% Strategy, BD, IT 8.0% 6.7%\nCanada 9.5% 8.4% Note: As of third quarter, 2021, new divisions (Communication and\nPolicy, Population Health & Sustainability and Strategy, BD, IT) added\nto our organization.\n1 I ncludes all types of turnover of regular employees. Regular employees\n1 I ncludes all types of turnover of regular employees. Regular employees\nare defined as employees who do not have a predetermined end date\nare defined as employees who do not have a predetermined end date\nto employment.\nto employment.\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t125"
  },
  {
    "page": 125,
    "source": "table",
    "content": "Turnover\n(global)\t2017\t2018\t2019\t2020\t2021\nOverall\nturnover rate1\t10.7%\t11.8%\t9.9%\t8.5%\t11.1%\nVoluntary\nturnover rate\t6.5%\t6.8%\t6.9%\t6.0%\t8.8%\n1 I ncludes all types of turnover of regular employees. Regular employees\nare defined as employees who do not have a predetermined end date"
  },
  {
    "page": 125,
    "source": "table",
    "content": "Turnover by\ndivision (2021)\tOverall\nturnover\nrate 1\tVoluntary\nturnover\nrate\nAnimal Health\t8.4%\t6.2%\nCommunication\nand Policy\t8.4%\t7.9%\nCorp Compliance\t4.4%\t4.4%\nGlobal Services\t9.8%\t8.2%\nGlobal Human Health\t16.2%\t12.6%\nHuman Resources\t13.9%\t9.5%\nLegal, Security,\nSafety &\nEnvironment\t8.3%\t6.9%\nManufacturing\nDivision\t8.7%\t6.1%\nResearch\nLaboratories\t9.6%\t8.9%\nPopulation Health &\nSustainability\t9.2%\t7.4%\nStrategy, BD, IT\t8.0%\t6.7%"
  },
  {
    "page": 125,
    "source": "table",
    "content": "Turnover\ndistribution\nby gender and\nregion (2021)\tFemale\tMale\nOverall\t48%\t52%\nAsia Pacific\t49%\t51%\nEEMEA\t50%\t50%\nLatin America\t48%\t52%\nEurope\t45%\t55%\nJapan\t42%\t58%\nU.S.\t47%\t53%\nChina\t52%\t48%\nCanada\t54%\t46%"
  },
  {
    "page": 125,
    "source": "table",
    "content": "Turnover by\nregion (2021)\tOverall\nturnover\nrate 1\tVoluntary\nturnover\nrate\nAsia Pacific\t12.6%\t10.3%\nLatin America\t11.3%\t5.7%\nEEMEA (Eastern\nEurope, Middle\nEast and Africa)\t15.5%\t9.4%\nJapan\t3.1%\t2.6%\nEurope\t8.6%\t5.4%\nU.S.\t8.7%\t8.0%\nChina\t29.2%\t25.0%\nCanada\t9.5%\t8.4%"
  },
  {
    "page": 126,
    "source": "table",
    "content": "CONTINUED: GRI 401-1 | SASB 330a.1 | SASB 330a.2\nEmployee hires by region 2017 2018 2019 2020 2021\nAsia Pacific (excl. China for years 2020 & 2021)\nNumber of hires 1,909 3,071 2,727 597 588\nHire rate1 16.1% 24.4% 20.8% 8.9% 10.0%\nEEMEA\nNumber of hires 378 505 605 360 373\nHire rate1 13.7% 16.7% 18.8% 10.7% 13.8%\nLatin America\nNumber of hires 1,246 714 558 459 496\nHire rate1 23.8% 13.1% 10.5% 8.4% 10.5%\nEurope and Canada (excl. Canada for years 2020 & 2021)\nNumber of hires 1,865 2,495 2,624 1,754 1,709\nHire rate1 9.8% 12.3% 12.3% 8.4% 9.5%\nJapan\nNumber of hires 109 153 121 143 120\nHire rate1 2.8% 4.3% 3.4% 4.4% 3.8%\nU.S.\nNumber of hires 2,173 3,019 2,654 3,193 3,443\nHire rate1 9.1% 12.4% 10.5% 11.9% 13.1%\nChina\nNumber of hires NR NR NR 2,149 1,907\nHire rate1 NR NR NR 29.5% 31.5%\nCanada\nNumber of hires NR NR NR 50 73\nHire rate1 NR NR NR 7.5% 12.8%\nNR: Not reported.\n1 Percentage of new hires in the total onboard head count; regular employees only. Regular employees are defined as employees who do not have a predetermined end date to employment.\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t126"
  },
  {
    "page": 126,
    "source": "table",
    "content": "Employee hires by region\t2017\t2018\t2019\t2020\t2021\nAsia Pacific (excl. China for years 2020 & 2021)\t\t\t\t\t\nNumber of hires\t1,909\t3,071\t2,727\t597\t588\nHire rate1\t16.1%\t24.4%\t20.8%\t8.9%\t10.0%\nEEMEA\t\t\t\t\t\nNumber of hires\t378\t505\t605\t360\t373\nHire rate1\t13.7%\t16.7%\t18.8%\t10.7%\t13.8%\nLatin America\t\t\t\t\t\nNumber of hires\t1,246\t714\t558\t459\t496\nHire rate1\t23.8%\t13.1%\t10.5%\t8.4%\t10.5%\nEurope and Canada (excl. Canada for years 2020 & 2021)\t\t\t\t\t\nNumber of hires\t1,865\t2,495\t2,624\t1,754\t1,709\nHire rate1\t9.8%\t12.3%\t12.3%\t8.4%\t9.5%\nJapan\t\t\t\t\t\nNumber of hires\t109\t153\t121\t143\t120\nHire rate1\t2.8%\t4.3%\t3.4%\t4.4%\t3.8%\nU.S.\t\t\t\t\t\nNumber of hires\t2,173\t3,019\t2,654\t3,193\t3,443\nHire rate1\t9.1%\t12.4%\t10.5%\t11.9%\t13.1%\nChina\t\t\t\t\t\nNumber of hires\tNR\tNR\tNR\t2,149\t1,907\nHire rate1\tNR\tNR\tNR\t29.5%\t31.5%\nCanada\t\t\t\t\t\nNumber of hires\tNR\tNR\tNR\t50\t73\nHire rate1\tNR\tNR\tNR\t7.5%\t12.8%"
  },
  {
    "page": 127,
    "source": "table",
    "content": "GRI 401-2\nSASB 330a.1\nSASB 330a.2"
  },
  {
    "page": 127,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t127"
  },
  {
    "page": 128,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t128"
  },
  {
    "page": 129,
    "source": "table",
    "content": "Employees and compensation 2017 2018 2019 2020 2021\nTotal compensation paid to employees/payroll, $8.65 $8.98 $9.56 $10.18 $9.92\nincluding benefits (in billions)\t\t\n\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 129,
    "source": "table",
    "content": "Employees and compensation\t2017\t2018\t2019\t2020\t2021\nTotal compensation paid to employees/payroll,\nincluding benefits (in billions)\t$8.65\t$8.98\t$9.56\t$10.18\t$9.92"
  },
  {
    "page": 130,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t130"
  },
  {
    "page": 131,
    "source": "table",
    "content": "Employee volunteering\t2017\t2018\t2019\t2020\t2021\nEmployees who volunteered 1\t6,560\t6,557\t14,395\t985\t1,786\nEmployees who used paid time off (PTO) 2\t4,870\t4,795\t7,301\t411\t883\nTotal recorded volunteer hours (TRVH)\t114,903\t114,393\t136,014\t46,278\t68,300\nSkilled volunteer hours 3\t19,468\t18,317\t19,907\t3,977\t16,904"
  },
  {
    "page": 131,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t131"
  },
  {
    "page": 132,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t132"
  },
  {
    "page": 133,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t133"
  },
  {
    "page": 134,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t134"
  },
  {
    "page": 135,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t135"
  },
  {
    "page": 136,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t136"
  },
  {
    "page": 137,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t137"
  },
  {
    "page": 138,
    "source": "table",
    "content": "GRI 403-9\nGRI 403-10"
  },
  {
    "page": 138,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t138"
  },
  {
    "page": 139,
    "source": "table",
    "content": "Lost time injuries by business\narea (total: 63) (2021) % of total1\nManufacturing (MMD) 39.7\nAnimal Health Intelligence 22.2\nHuman Health (HH) 17.5\nAnimal Health 12.7\nResearch (MRL) 3.2\nFacility Management 3.2\nGlobal Support Functions 1.6\n(Legal, HR, IT, S&E et al.)\nCases by business Lost time Recordable\narea (#) (2021) cases cases\nManufacturing (MMD) 25 84\nAnimal Health Intelligence 14 22\nHuman Health (HH) 11 22\nAnimal Health 8 12\nResearch (MRL) 2 10\nFacility Management 2 7\nGlobal Support Functions 1 3\n(Legal, HR, IT, S&E et al.)\nTotal 63 160\n1 M ay not total 100 percent due to rounding.\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 139,
    "source": "table",
    "content": "Lost time injuries by business\narea (total: 63) (2021)\t% of total1\nManufacturing (MMD)\t39.7\nAnimal Health Intelligence\t22.2\nHuman Health (HH)\t17.5\nAnimal Health\t12.7\nResearch (MRL)\t3.2\nFacility Management\t3.2\nGlobal Support Functions\n(Legal, HR, IT, S&E et al.)\t1.6"
  },
  {
    "page": 139,
    "source": "table",
    "content": "Cases by business\narea (#) (2021)\tLost time\ncases\tRecordable\ncases\nManufacturing (MMD)\t25\t84\nAnimal Health Intelligence\t14\t22\nHuman Health (HH)\t11\t22\nAnimal Health\t8\t12\nResearch (MRL)\t2\t10\nFacility Management\t2\t7\nGlobal Support Functions\n(Legal, HR, IT, S&E et al.)\t1\t3\nTotal\t63\t160"
  },
  {
    "page": 140,
    "source": "table",
    "content": "CONTINUED: GRI 403-9 | GRI 403-10\nRecordable injuries by casual factors (total: 160) (2021) % of total\nSlips/trips/fall 26.9\nStruck by/caught in 28.1\nMotor vehicle 7.5\nErgonomic 20.0\nChemical exposure 3.1\nBiological exposure 2.5\nOther 1.3\nNon-ergonomic 2.5\nPhysical/environmental exposure 8.1\nLost time injuries/illnesses by casual factors (2021) Lost time cases % of lost time cases\nSlips/trips/fall 21 33.3\nStruck by/caught in 10 15.9\nMotor vehicle 8 12.7\nErgonomic 15 23.8\nChemical exposure 2 3.2\nBiological exposure 1 1.6\nOther 0 0.0\nNon-ergonomic 0 0.0\nPhysical/environmental exposure 6 9.5\nTotal 63 100\t\t\nMerck ESG Progress Report 2021/2022\tMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t140"
  },
  {
    "page": 140,
    "source": "table",
    "content": "Recordable injuries by casual factors (total: 160) (2021)\t% of total\nSlips/trips/fall\t26.9\nStruck by/caught in\t28.1\nMotor vehicle\t7.5\nErgonomic\t20.0\nChemical exposure\t3.1\nBiological exposure\t2.5\nOther\t1.3\nNon-ergonomic\t2.5\nPhysical/environmental exposure\t8.1"
  },
  {
    "page": 140,
    "source": "table",
    "content": "Lost time injuries/illnesses by casual factors (2021)\tLost time cases\t% of lost time cases\nSlips/trips/fall\t21\t33.3\nStruck by/caught in\t10\t15.9\nMotor vehicle\t8\t12.7\nErgonomic\t15\t23.8\nChemical exposure\t2\t3.2\nBiological exposure\t1\t1.6\nOther\t0\t0.0\nNon-ergonomic\t0\t0.0\nPhysical/environmental exposure\t6\t9.5\nTotal\t63\t100"
  },
  {
    "page": 141,
    "source": "table",
    "content": "CONTINUED: GRI 403-9 | GRI 403-10\nGlobal safety performance (employees)1, 2 2017 2018 2019 2020 2021\nWorkplace safety\nRecordable incident rate (RIR) 0.33 0.30 0.30 0.16 0.20\nRIR percentage change -6% -9% 0% -47% 25%\nLost time incident rate (LTIR) 0.13 0.10 0.11 0.05 0.08\nFatalities3 0 2 0 0 0\nMotor vehicle safety\nCollisions per million miles (CPMM)4 7.29 6.93 7.01 5.07 6.11\nNote: Injury rates are subject to change over time as new cases are added, and case classifications change in accordance with our own requirements and applicable regulatory requirements.\n1 LTIR/RIR: Calculated per OSHA methodology.\n² Newly acquired facilities are not included in this data set.\n3 In 2018, one fatality was transportation-related, one high-risk work related.\n4 CPMM: Reflects both personal and business use of Company-owned or -leased vehicles.\nGlobal safety performance (non-employees) 2017 2018 2019 2020 2021\nCapital projects construction safety1,2\nRIR 0.59 0.73 0.42 0.60 0.28\nDART3 0.32 0.28 0.15 0.24 0.11\nFatalities 0 0 0 0 0\nFacility management contractor safety4\nRIR N/A 0.71 0.55 0.35 0.60\nLTIR N/A 0.47 0.42 0.26 0.27\nFatalities N/A 0 0 0 0\nNote: Injury rates are subject to change over time as new cases are added, and case classifications change in accordance with our own requirements and applicable regulatory requirements.\nN/A: Not available.\n1 LTIR/RIR: Calculated per OSHA methodology.\n2 Primarily reflects capital projects over $100,000 managed by our global engineering group.\n³ DART: days away, reassigned or transferred, calculated per OSHA 300 methodology.\n⁴ Incident rates for IFM partners; reporting initiated in 2018.\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t141"
  },
  {
    "page": 141,
    "source": "table",
    "content": "Global safety performance (employees)1, 2\t2017\t2018\t2019\t2020\t2021\nWorkplace safety\t\t\t\t\t\nRecordable incident rate (RIR)\t0.33\t0.30\t0.30\t0.16\t0.20\nRIR percentage change\t-6%\t-9%\t0%\t-47%\t25%\nLost time incident rate (LTIR)\t0.13\t0.10\t0.11\t0.05\t0.08\nFatalities3\t0\t2\t0\t0\t0\nMotor vehicle safety\t\t\t\t\t\nCollisions per million miles (CPMM)4\t7.29\t6.93\t7.01\t5.07\t6.11"
  },
  {
    "page": 141,
    "source": "table",
    "content": "Global safety performance (non-employees)\t2017\t2018\t2019\t2020\t2021\nCapital projects construction safety1,2\t\t\t\t\t\nRIR\t0.59\t0.73\t0.42\t0.60\t0.28\nDART3\t0.32\t0.28\t0.15\t0.24\t0.11\nFatalities\t0\t0\t0\t0\t0\nFacility management contractor safety4\t\t\t\t\t\nRIR\tN/A\t0.71\t0.55\t0.35\t0.60\nLTIR\tN/A\t0.47\t0.42\t0.26\t0.27\nFatalities\tN/A\t0\t0\t0\t0"
  },
  {
    "page": 142,
    "source": "table",
    "content": "Training and\neducation1 2017 2018 2019 2020 2021\nTotal course 5.3 4.4 5.3 7.2 6.3\ncompletions for\nall learners\n(in millions)\nHours of training 2.6 2.2 2.7 3.6 3.2\nfor all learners\n(in millions)2\nAverage course 48 43 55 69 51\ncompletions\nper learner\n1 “ All learners” is defined as all active regular and part time employees, as well as contingent workers.\n2 B ased on average of 30 minutes per course.\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t142"
  },
  {
    "page": 142,
    "source": "table",
    "content": "Training and\neducation1\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t6.3\n\t\t\t\t\t3.2\n\t\t\t\t\t51"
  },
  {
    "page": 143,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t143"
  },
  {
    "page": 144,
    "source": "table",
    "content": "Business Leadership Program\t2021\nPost-program retention\t85%\nLateral moves\t34%\nPromotions\t31%"
  },
  {
    "page": 144,
    "source": "table",
    "content": "GMAP\t2021\nPost-program retention\t92%\nLateral moves\t33%\nPromotions\t24%"
  },
  {
    "page": 144,
    "source": "table",
    "content": "Leadership Pathway\t2021\nPost-program retention\t96%\nLateral moves\t23%\nPromotions\t14%"
  },
  {
    "page": 144,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t144"
  },
  {
    "page": 145,
    "source": "table",
    "content": "Women’s Leadership Program\t2021\nPost-program retention\t78%\nLateral moves\t37%\nPromotions\t27%"
  },
  {
    "page": 145,
    "source": "table",
    "content": "Rise\t2021\nPost-program retention\t97%\nLateral moves\t12%\nPromotions\t12%"
  },
  {
    "page": 145,
    "source": "table",
    "content": "Diverse Leader Program\t2021\nPost-program retention\t82%\nLateral moves\t34%\nPromotions\t36%"
  },
  {
    "page": 145,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t145"
  },
  {
    "page": 146,
    "source": "table",
    "content": "Promotion metrics1\t2019\t2020\t2021\nMen\t47%\t48%\t47%\nWomen\t53%\t52%\t53%"
  },
  {
    "page": 146,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t146"
  },
  {
    "page": 147,
    "source": "table",
    "content": "Performance reviews\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t100%\n\t\t\t\t\t100%\n\t\t\t\t\t100%\n\t\t\t\t\t95%"
  },
  {
    "page": 147,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t147"
  },
  {
    "page": 148,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t148"
  },
  {
    "page": 149,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t149"
  },
  {
    "page": 150,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t150"
  },
  {
    "page": 151,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t151"
  },
  {
    "page": 152,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t152"
  },
  {
    "page": 153,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t153"
  },
  {
    "page": 154,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t154"
  },
  {
    "page": 155,
    "source": "table",
    "content": "$2.9 billion\nspending with diverse\nsuppliers globally"
  },
  {
    "page": 155,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t155"
  },
  {
    "page": 156,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t156"
  },
  {
    "page": 157,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t157"
  },
  {
    "page": 158,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t158"
  },
  {
    "page": 159,
    "source": "table",
    "content": "Female representation,\nby job category (global) 2017 2018 2019 2020 2021\nBoard1 23% 33% 46% 46% 43%\nExecutives2 22% 20% 20% 33% 33%\nSenior management3 25% 27% 30% 31% 36%\nAll managers4 39% 41% 42% 42% 44%\nAll employees 49% 49% 49% 50% 50%\nNew hires 49% 51% 51% 50% 53%\nPromotions 52% 52% 53% 52% 53%\nNote: We have publicly disclosed EEO-1 information since 1999. Our 2021 data is available on the ESG Resources page of our corporate website. All data, except for those corresponding\nto our Board members, is as of December 31, 2021. All Board figures above are derived from our proxy statement filed the following year. To align with U.S. government reporting\nrequirements, the ESG data for gender diversity in this report uses the terms men and women. We recognize and embrace the gender spectrum and diversity in our employees, and have\ninternally established voluntary Self-ID options for employees to self-report on their gender identity. The totals in this report may not equal 100 percent due to rounding or employees\nwho have not reported their gender and/or race/ethnicity.\n1 Data for Board members are derived from our proxy statement filed the following year.\n2 “Executive” is defined as the executive committee who reports to the chief executive officer.\n3 “Senior management team” is defined as vice presidents and above, not on executive committee.\n4 “Management role” is defined as all other managers with at least one direct report.\t\t\n\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices"
  },
  {
    "page": 159,
    "source": "table",
    "content": "Female representation,\nby job category (global)\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t43%\n\t\t\t\t\t33%\n\t\t\t\t\t36%\n\t\t\t\t\t44%\n\t\t\t\t\t50%\n\t\t\t\t\t53%\n\t\t\t\t\t53%"
  },
  {
    "page": 160,
    "source": "table",
    "content": "CONTINUED: GRI 405-1\nGender and ethnicity 2017 2018 2019 2020 2021\nWomen in the workforce 49% 49% 49% 50% 50%\nWomen on the Board1 23% 33% 46% 46% 43%\nWomen in executive roles2 22% 20% 20% 33% 33%\nWomen on the senior management team3 25% 27% 30% 31% 36%\nWomen in management roles4 39% 41% 42% 42% 44%\nMembers of underrepresented ethnic groups on the Board 15% 17% 23% 31% 21%\nMembers of underrepresented ethnic groups in executive roles (U.S.)2 33% 30% 40% 25% 42%\nMembers of underrepresented ethnic groups on the senior management 17% 19% 21% 20% 25%\nteam (U.S.)3\nMembers of underrepresented ethnic groups in the workforce (U.S.) 26% 28% 29% 30% 32%\nMembers of underrepresented ethnic groups in management roles (U.S.)4 20% 22% 23% 25% 26%\nNew hires that were female 49% 51% 51% 50% 53%\nPromotions that were female 52% 52% 53% 52% 53%\nNew hires that were members of underrepresented ethnic groups (U.S.) 37% 36% 35% 40% 46%\nPromotions that were members of underrepresented ethnic groups (U.S.) 28% 28% 30% 32% 34%\nNote: We have publicly disclosed EEO-1 information since 1999. Our 2021 data is available on the ESG Resources page of our corporate website. To align with U.S. government reporting\nrequirements, the ESG data for gender diversity in this report uses the terms men and women. We recognize and embrace the gender spectrum and diversity in our employees, and have\ninternally established voluntary Self-ID options for employees to self-report on their gender identity. The totals in this report may not equal 100 percent due to rounding or employees who\nhave not reported their gender and/or race/ethnicity.\n1 All Board figures above are derived from our proxy statement filed the following year.\n2 “Executive” is defined as the executive committee who reports to the chief executive officer.\n3 “Senior management team” is defined as vice presidents and above, not on executive committee.\n4 “Management role” is defined as all other managers with at least one direct report.\t\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t160"
  },
  {
    "page": 160,
    "source": "table",
    "content": "Gender and ethnicity\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t50%\n\t\t\t\t\t43%\n\t\t\t\t\t33%\n\t\t\t\t\t36%\n\t\t\t\t\t44%\n\t\t\t\t\t21%\n\t\t\t\t\t42%\n\t\t\t\t\t25%\n\t\t\t\t\t32%\n\t\t\t\t\t26%\n\t\t\t\t\t53%\n\t\t\t\t\t53%\n\t\t\t\t\t46%\n\t\t\t\t\t34%"
  },
  {
    "page": 161,
    "source": "table",
    "content": "Underrepresented ethnic\ngroup (UEG) representation,\nby ethnicity (U.S.) (2021)\tTotal\tBlack/\nAfrican\nAmerican\tLatino/\nHispanic\tAsian\tAll other\n\t21%\t\t\t\t\n\t42%\t\t\t\t\n\t25%\t\t\t\t\n\t26%\t\t\t\t\n\t32%\t\t\t\t\n\t46%\t\t\t\t\n\t34%"
  },
  {
    "page": 161,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t161"
  },
  {
    "page": 162,
    "source": "table",
    "content": "CONTINUED: GRI 412\nWe’ve put in place appropriate policies, processes, training and monitoring systems to address key human rights issues. Support and respect for the protection of human rights\nis embedded and reflected in our operational policies and procedures, as summarized in the table below.\nHuman rights issue Policies / standards Governance\ntnemeganaM\nreilppuS gnidnopseR ni\necneloiV smraeriF\nyciloP\nyciloP dradnatS\nsthgiR yciloP yciloP namuH yciloP yciloP & tnemerucorP yciloP rentraP tcudnoC noitamrofnI noitcetorP ataD yciloP & tcudnocsiM fo fo\nsecruoseR & snoitaleR ssenisuB & noitcetorP gnitropeR noitneverP ecapkroW noissessoP dradnatS\nnamuH cilbuP namuH & robaL sthgiR htlaeH ytefaS fo edoC ycavirP\nLead function & ot\nHealth & safety X X X X Global Safety & Environment\nForced labor and human trafficking X X Human Resources\nDiscrimination and harassment X X X Human Resources\nChild labor X X Human Resources\nFreedom of association X X Human Resources\nWorking hours X X Human Resources\nPrivacy X X X Global Privacy Office\nSecurity X X X Global Security\nAccess to grievance mechanisms X X X X X X X X X X Office of Ethics\nSuppliers and business partners X X X Global Supplier Management\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t162"
  },
  {
    "page": 162,
    "source": "table",
    "content": "Human rights issue\tPolicies / standards\t\t\t\t\t\t\t\t\t\t\tGovernance\n\tsthgiR\nyciloP\nnamuH\ncilbuP\tyciloP\nsecruoseR\nnamuH\tnamuH\nyciloP\n&\nsthgiR\nrobaL\tyciloP\n&\nhtlaeH ytefaS\treilppuS\n& yciloP\ntnemerucorP\nsnoitaleR\trentraP tcudnoC\nssenisuB\nfo\nedoC\ttnemeganaM\nyciloP\nnoitcetorP\nnoitamrofnI\n&\tyciloP\nataD\nnoitcetorP\n&\nycavirP\tgnidnopseR\nyciloP\ntcudnocsiM\n&\ngnitropeR\not\tni\necneloiV\ndradnatS\nfo\nnoitneverP\necapkroW\tsmraeriF\nfo\nnoissessoP\ndradnatS\t\n\tX\tX\tX\tX\t\t\t\t\t\t\t\t\n\tX\t\tX\t\t\t\t\t\t\t\t\t\n\tX\tX\tX\t\t\t\t\t\t\t\t\t\n\tX\t\tX\t\t\t\t\t\t\t\t\t\n\tX\t\tX\t\t\t\t\t\t\t\t\t\n\tX\t\tX\t\t\t\t\t\t\t\t\t\n\tX\t\t\t\t\t\tX\tX\t\t\t\t\n\t\tX\t\t\t\t\t\t\t\tX\tX\t\n\tX\tX\tX\tX\tX\tX\tX\t\tX\tX\tX\t\n\t\t\tX\t\tX\tX"
  },
  {
    "page": 163,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t163"
  },
  {
    "page": 164,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t164"
  },
  {
    "page": 165,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t165"
  },
  {
    "page": 166,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t166"
  },
  {
    "page": 167,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOve"
  },
  {
    "page": 168,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t168"
  },
  {
    "page": 169,
    "source": "table",
    "content": "Quality and product safety 2017 2018 2019 2020 2021\nNumber of product recalls in the United States1,2 0 2 1 2 2\nPercentage of sold units recalled during a given year 0.01% 0.17% 0.01% 0.50% 0.22%\n(recall rate globally)1,2\n1 Definition of Recall Classifications.\n2 Starting with June 2021, information for Organon was removed due to spin-off."
  },
  {
    "page": 169,
    "source": "table",
    "content": "GRI 416-2\nSASB 250a.1\nSASB 250a.2\nSASB 250a.3\nSASB 260a.1\nSASB 260a.2"
  },
  {
    "page": 169,
    "source": "table",
    "content": "Quality and product safety\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t2\n\t\t\t\t\t0.22%"
  },
  {
    "page": 169,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t169"
  },
  {
    "page": 170,
    "source": "table",
    "content": "Anti-counterfeiting1 2017 2018 2019 2020 2021\nInvestigations of suspected counterfeit products2 137 269 563 554 964\nSubstantiated cases of counterfeit products 76 231 212 77 86\n1 Prior-year data have been adjusted to reflect the current status of each event as of March 2022.\n2 Evidence from ongoing investigations of suspected counterfeit products can result in recategorization.\t\t\nMerck ESG Progress Report 2021/2022\t\t\t\n\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t170"
  },
  {
    "page": 170,
    "source": "table",
    "content": "Anti-counterfeiting1\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t964\n\t\t\t\t\t86"
  },
  {
    "page": 171,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t171"
  },
  {
    "page": 172,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t172"
  },
  {
    "page": 173,
    "source": "table",
    "content": "Phase II-V clinical trials patients by region1\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t18%\n\t\t\t\t\t29%\n\t\t\t\t\t20%\n\t\t\t\t\t14%\n\t\t\t\t\t20%"
  },
  {
    "page": 173,
    "source": "table",
    "content": "Trial disclosures activities\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t611\n\t\t\t\t\t79"
  },
  {
    "page": 173,
    "source": "table",
    "content": "GCP/PV inspections\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t0"
  },
  {
    "page": 173,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t173"
  },
  {
    "page": 174,
    "source": "table",
    "content": "GRI 417-1\nSASB 270a.2"
  },
  {
    "page": 174,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t174"
  },
  {
    "page": 175,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t175"
  },
  {
    "page": 176,
    "source": "table",
    "content": "Merck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t176"
  },
  {
    "page": 177,
    "source": "table",
    "content": "Global privacy program 2017 2018 2019 2020 2021\nNumber of concerns regarding privacy practices, breaches of 123 315 292 2503 4263\nprivacy and losses of personal data that were substantiated1\nNumber of privacy breaches requiring notification by 0 2 2 0 3\nour Company to individuals or government authorities\n1 P rivacy concerns reported here include all concerns about our privacy practices reported to our Company’s Privacy Office and substantiated or verified. Verified concerns are investigated as\npart of our Incident Management Process, which includes a determination of whether regulatory or data subject notification is required.\n2 Change in reporting criteria to exclude non-privacy, quality related issues from the data.\n3 Increased sensitivity of network traffic monitors contributed to increased number in 2020 and 2021.\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t177"
  },
  {
    "page": 177,
    "source": "table",
    "content": "Global privacy program\t2017\t2018\t2019\t2020\t2021\n\t\t\t\t\t4263\n\t\t\t\t\t3"
  },
  {
    "page": 178,
    "source": "table",
    "content": "Global Reporting\nInitiative (GRI)\t\tThe GRI Standards represent global best practices for reporting publicly on a range of economic,\nenvironmental and social impacts. The table below summarizes where responses to the GRI\ndisclosures can be found throughout this report.\t\n\tGeneral Disclosures\nGRI 102 Organizational Profile\n102-1 Organization name (Core) Pages 27–29\n102-2 Primary brands, products, and services (Core) Pages 27–29\n102-3 Headquarters location (Core) Pages 27–29\n102-4 Location of operations (Core) Pages 27–29\n102-5 Ownership and legal form (Core) Pages 27–29\n102-6 Markets served (Core) Pages 27–29\n102-7 Scale of the organization (Core) Pages 27–29\n102-8 Information on employees and other workers (Core) Pages 27–29\n102-9 Supply chain (Core) Pages 30-34\n102-10 Organizational changes during the reporting period (Core) Page 34\n102-11 Precautionary principle (Core) Page 35\n102-12 External initiatives (Core) Pages 35-36\n102-13 Membership associations (Core) Pages 36-38\nGRI 102 Strategy\n102-14 CEO Letter (Core) Page 39\n102-15 Key impacts, risks, and opportunities Not reported\t\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t178"
  },
  {
    "page": 178,
    "source": "table",
    "content": "GRI 102 Organizational Profile\t\n\tPages 27–29\n\tPages 27–29\n\tPages 27–29\n\tPages 27–29\n\tPages 27–29\n\tPages 27–29\n\tPages 27–29\n\tPages 27–29\n\tPages 30-34\n\tPage 34\n\tPage 35\n\tPages 35-36\n\tPages 36-38\nGRI 102 Strategy\t\n\tPage 39\n\tNot reported"
  },
  {
    "page": 179,
    "source": "table",
    "content": "GRI 102 Ethics & Integrity\n102-16 Values, principles, standards, and norms of behavior (Core) Pages 39-40\n102-17 Mechanisms for advice and concerns about ethics Pages 39-40\nGRI 102 Governance\n102-18 Governance structure of the organization (Core) Pages 41-43\n102-19 Delegation of responsibility Pages 41-43\n102-20 High-level accountability for sustainability topics Pages 41-43\n102-21 Access to the Board Pages 41-43\n102-22 Composition of the Board and its committees Pages 41-43\n102-23 Chair of the highest governance body Pages 41-43\n102-24 Board nomination and selection processes Page 43\n102-25 Board conflicts of interest Page 43\n102-26 Board and executive roles Page 43\n102-27 Board ESG knowledge Pages 43-44\n102-28 Board performance Not reported\n102-29 Board identification of ESG impacts, risks, and opportunities Pages 43-44\n102-30 Board ESG review of risk management processes Pages 43-44\n102-31 Frequency of Board review Pages 43-44\n102-32 Report review Pages 43-44\n102-33 Board communication Page 44\n102-34 Concerns communicated to the Board Not reported\n102-35 Remuneration policies for the Board and senior executives Page 44\n102-36 Process for determining remuneration Page 44\n102-37 Remuneration shareholder resolutions Page 44\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t179"
  },
  {
    "page": 179,
    "source": "table",
    "content": "GRI 102 Ethics & Integrity\t\n\tPages 39-40\n\tPages 39-40\nGRI 102 Governance\t\n\tPages 41-43\n\tPages 41-43\n\tPages 41-43\n\tPages 41-43\n\tPages 41-43\n\tPages 41-43\n\tPage 43\n\tPage 43\n\tPage 43\n\tPages 43-44\n\tNot reported\n\tPages 43-44\n\tPages 43-44\n\tPages 43-44\n\tPages 43-44\n\tPage 44\n\tNot reported\n\tPage 44\n\tPage 44\n\tPage 44"
  },
  {
    "page": 180,
    "source": "table",
    "content": "102-38 CEO/employee pay ratio Page 44\n102-39 CEO/employee pay increase ratio Not reported\nGRI 102 Stakeholder Engagement\n102-40 Stakeholder engagement (Core) Pages 45-47\n102-41 Union representation (Core) Pages 45-47\n102-42 Stakeholder identification (Core) Pages 45-47\n102-43 Approach to stakeholder engagement (Core) Pages 45-47\n102-44 Key topics and concerns raised (Core) Pages 45-47\n2022 Proxy statement (page 25)\nGRI 102 Reporting Practice\n102-45 Entities included in financial statements (Core) Page 48\n102-46 Defining report content and topic boundaries (Core) Pages 48-50\n102-47 Material aspects included (Core) Pages 48-50\n102-48 Restatements (Core) Page 50\n102-49 Reporting changes (Core) Page 50\n102-50 Reporting period (Core) Page 50\n102-51 Date of most recent report (Core) Page 50\n102-52 Reporting cycle (Core) Page 50\n102-53 Report contact (Core) Page 50\n102-54 Claims of reporting in accordance with the GRI Standards (Core) Page 51\n102-55 GRI content index (Core) Page 51\n102-56 External assurance (Core) Page 51\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t180"
  },
  {
    "page": 180,
    "source": "table",
    "content": "Page 44\n\tNot reported\nGRI 102 Stakeholder Engagement\t\n\tPages 45-47\n\tPages 45-47\n\tPages 45-47\n\tPages 45-47\n\tPages 45-47\n2022 Proxy statement (page 25)\nGRI 102 Reporting Practice\t\n\tPage 48\n\tPages 48-50\n\tPages 48-50\n\tPage 50\n\tPage 50\n\tPage 50\n\tPage 50\n\tPage 50\n\tPage 50\n\tPage 51\n\tPage 51\n\tPage 51"
  },
  {
    "page": 181,
    "source": "table",
    "content": "Economic\nGRI 201 Economic Performance (2016)\n201-1 Direct economic value generated and distributed Pages 52-53\n201-2 Financial implications and other risks and opportunities due to climate change Pages 53-54\n201-3 Benefit plan coverage Page 54\nGRI 203 Indirect Economic Impacts (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 55-66\nfor evaluating the effectiveness of the company's strategy.\n203-1 Infrastructure investments and services supported Pages 67-74\n203-2 Indirect economic impacts Pages 67-74\nGRI 204 Procurement Practices (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 75-78\nfor evaluating the effectiveness of the company's strategy.\nGRI 205 Anti-corruption (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 78-79\nfor evaluating the effectiveness of the company's strategy.\n205-2 Communications and training on anti-corruption Page 79\nGRI 206 Anti-Competitive Behavior (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 80\nfor evaluating the effectiveness of the company's strategy.\n206-1 Anti-competitive behavior Page 81\nGRI 207 Tax (2019)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 82\nfor evaluating the effectiveness of the company's strategy.\n207-1 Approach to tax Page 82\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t181"
  },
  {
    "page": 181,
    "source": "table",
    "content": "GRI 201 Economic Performance (2016)\t\t\n\t\tPages 52-53\n\t\tPages 53-54\n\t\tPage 54\nGRI 203 Indirect Economic Impacts (2016)\t\t\n\t\tPages 55-66\n\t\tPages 67-74\n\t\tPages 67-74\nGRI 204 Procurement Practices (2016)\t\t\n\t\tPages 75-78\nGRI 205 Anti-corruption (2016)\t\t\n\t\tPages 78-79\n\t\tPage 79\nGRI 206 Anti-Competitive Behavior (2016)\t\t\n\t\tPage 80\n\t\tPage 81\nGRI 207 Tax (2019)\t\t\n\t\tPage 82\n\t\tPage 82"
  },
  {
    "page": 182,
    "source": "table",
    "content": "Environmental\nGRI 301 Materials (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 83–87\nfor evaluating the effectiveness of the company's strategy.\nGRI 302 Energy (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 88-90\nfor evaluating the effectiveness of the company's strategy.\n302-1 Energy consumption within the organization (Scopes 1 + 2) Pages 91-92\n302-4 Energy reductions Pages 91-92\nGRI 303 Water and Effluents (2018)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 93-94\nfor evaluating the effectiveness of the company's strategy.\n303-1 Water as a shared resource Page 95\n303-2 Water discharge-related impacts Pages 95-96\n303-3 Water withdrawal Pages 96-99\n303-4 Water discharge Pages 100-101\nGRI 304 Biodiversity (2016)\n304-2 Significant impacts of activities, products, and services on biodiversity Page 102\n304-3 Habitats protected or restored Page 103\nGRI 305 Emissions (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 104-105\nfor evaluating the effectiveness of the company's strategy.\n305-1 Direct GHG emissions (Scope 1) Pages 106-108\n305-2 Indirect GHG emissions (Scope 2) Pages 106-108\n305-3 Other indirect GHG emissions (Scope 3) Pages 106-108\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t182"
  },
  {
    "page": 182,
    "source": "table",
    "content": "GRI 301 Materials (2016)\t\t\n\t\tPages 83–87\nGRI 302 Energy (2016)\t\t\n\t\tPages 88-90\n\t\tPages 91-92\n\t\tPages 91-92\nGRI 303 Water and Effluents (2018)\t\t\n\t\tPages 93-94\n\t\tPage 95\n\t\tPages 95-96\n\t\tPages 96-99\n\t\tPages 100-101\nGRI 304 Biodiversity (2016)\t\t\n\t\tPage 102\n\t\tPage 103\nGRI 305 Emissions (2016)\t\t\n\t\tPages 104-105\n\t\tPages 106-108\n\t\tPages 106-108\n\t\tPages 106-108"
  },
  {
    "page": 183,
    "source": "table",
    "content": "305-4 GHG emissions intensity Pages 106-108\n305-5 Reduction of GHG emissions Pages 106-108\n305-6 Ozone-depleting substances (ODS) Pages 108-109\n305-7 NOx, SOx and other emissions Pages 108-109\nGRI 306 Waste (2020)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 110\nfor evaluating the effectiveness of the company's strategy.\n306-1 Waste generation and significant waste-related impacts Pages 111-112\n306-2 Management of significant waste-related impacts Pages 111-112\n306-3 Waste generated Pages 113-116\n306-4 Waste diverted from disposal Pages 113-116\n306-5 Waste directed to disposal Pages 113-116\nGRI 307 Environmental Compliance (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 116-120\nfor evaluating the effectiveness of the company's strategy.\n307-1 Non-compliance with environmental laws and regulations Page 121\nGRI 308 Supplier Environmental Assessment (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 122-123\nfor evaluating the effectiveness of the company's strategy.\nSocial\nGRI 401 Employment (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 124\nfor evaluating the effectiveness of the company's strategy.\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t183"
  },
  {
    "page": 183,
    "source": "table",
    "content": "Pages 106-108\n\tPages 106-108\n\tPages 108-109\n\tPages 108-109\nGRI 306 Waste (2020)\t\n\tPage 110\n\tPages 111-112\n\tPages 111-112\n\tPages 113-116\n\tPages 113-116\n\tPages 113-116\nGRI 307 Environmental Compliance (2016)\t\n\tPages 116-120\n\tPage 121\nGRI 308 Supplier Environmental Assessment (2016)\t\n\tPages 122-123"
  },
  {
    "page": 183,
    "source": "table",
    "content": "GRI 401 Employment (2016)\t\n\tPage 124"
  },
  {
    "page": 184,
    "source": "table",
    "content": "401-1 New employee hires and turnover Pages 125-127\n401-2 Benefits provided to full-time employees Pages 127-131\n401-3 Parental leave Page 131\nGRI 403 Occupational Health & Safety (2018)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 131-132\nfor evaluating the effectiveness of the company's strategy.\n403-1 Occupational health and safety management system Page 132\n403-2 Hazard identification, risk assessment, and incident investigation Pages 132-136\n403-3 Occupational health services Pages 136-137\n403-5 Worker training on occupational health and safety Page 137\n403-6 Promotion of worker health Page 138\n403-9 Work-related injuries Pages 138-141\n403-10 Work-related ill health Pages 138-141\nGRI 404 Training & Education (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 142\nfor evaluating the effectiveness of the company's strategy.\n404-1 Average hours of employee training Page 142\n404-2 Programs for upgrading employee skills and transition assistance programs Pages 143-146\n404-3 Percentage of employees receiving regular performance reviews Page 147\nGRI 405 Diversity & Equal Opportunity (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 148-158\nfor evaluating the effectiveness of the company's strategy.\n405-1 Diversity of governance bodies and employees Pages 159-161\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t184"
  },
  {
    "page": 184,
    "source": "table",
    "content": "Pages 125-127\n\tPages 127-131\n\tPage 131\nGRI 403 Occupational Health & Safety (2018)\t\n\tPages 131-132\n\tPage 132\n\tPages 132-136\n\tPages 136-137\n\tPage 137\n\tPage 138\n\tPages 138-141\n\tPages 138-141\nGRI 404 Training & Education (2016)\t\n\tPage 142\n\tPage 142\n\tPages 143-146\n\tPage 147\nGRI 405 Diversity & Equal Opportunity (2016)\t\n\tPages 148-158\n\tPages 159-161"
  },
  {
    "page": 185,
    "source": "table",
    "content": "GRI 412 Human Rights Assessment (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 161-163\nfor evaluating the effectiveness of the company's strategy.\n412-1 Operations that have been subject to human rights reviews Page 163\n412-2 Employee training on human rights policies and procedures Page 163\n412-3 Investment agreements and contracts that include human rights clauses or underwent screening Page 163\nGRI 414 Supplier Social Assessment (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 164-166\nfor evaluating the effectiveness of the company's strategy.\n414-1 New suppliers screened using social criteria Page 166\nGRI 415 Public Policy (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 166\nfor evaluating the effectiveness of the company's strategy.\n415-1 Political contributions Pages 166-167\nGRI 416 Customer Health & Safety (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 167-168\nfor evaluating the effectiveness of the company's strategy.\n416-2 Incidents of non-compliance concerning the health and safety impacts of products and services Pages 169-173\nGRI 417 Marketing & Labeling (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 174\nfor evaluating the effectiveness of the company's strategy.\n417-1 Requirements for product and service information and labeling Pages 174-175\nGRI 418 Customer Privacy (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 175-177\nfor evaluating the effectiveness of the company's strategy.\n418-1 Substantiated complaints regarding breaches of customer privacy and losses of customer data Page 177\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t185"
  },
  {
    "page": 185,
    "source": "table",
    "content": "GRI 412 Human Rights Assessment (2016)\t\t\n\t\tPages 161-163\n\t\tPage 163\n\t\tPage 163\n\t\tPage 163\nGRI 414 Supplier Social Assessment (2016)\t\t\n\t\tPages 164-166\n\t\tPage 166\nGRI 415 Public Policy (2016)\t\t\n\t\tPage 166\n\t\tPages 166-167\nGRI 416 Customer Health & Safety (2016)\t\t\n\t\tPages 167-168\n\t\tPages 169-173\nGRI 417 Marketing & Labeling (2016)\t\t\n\t\tPage 174\n\t\tPages 174-175\nGRI 418 Customer Privacy (2016)\t\t\n\t\tPages 175-177\n\t\tPage 177"
  },
  {
    "page": 186,
    "source": "table",
    "content": "Sustainability Account\nStandards Board (SAS\t\ting\nB)\tSASB is an independent standards-setting organization dedicated to improving the\neffectiveness and comparability of corporate disclosure on ESG factors. The table\nbelow summarizes how our existing reporting aligns with the recommended metrics\nfor the Biotechnology & Pharmaceuticals Standard within the Health Care sector,\nand where this information can be found in this report.\t\t\n\tSafety of clinical trial participants\n210a.1 Discussion, by world region, of management process for ensuring quality and patient safety Not reported\nduring clinical trials\n210a.2 Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance Not reported\nthat resulted in: Voluntary Action Indicated (VAI) and Official Action Indicated (OAI)\n210a.3 Total amount of monetary losses as a result of legal proceedings associated with clinical trials Not reported\nin developing countries\nAccess to medicines\n240a.1 Description of actions and initiatives to promote access to health care products for priority Pages 55-66\ndiseases and in priority countries as defined by the Access to Medicine Index\n240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification Pages 55-66\nof Medicines Programme (PQP)\nAffordability and pricing\n240b.1 Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved Not reported\npayments and/or provisions to delay bringing an authorized generic product to market for a\ndefined time period\n240b.2 Percentage change in: average list price and average net price across U.S. product portfolio Pages 55-66\ncompared to previous year\n240b.3 Percentage change in: list price and net price of product with largest increase compared to Pages 55-66\nprevious year\t\t\t\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t\t186"
  },
  {
    "page": 186,
    "source": "table",
    "content": "Safety of clinical trial participants\t\n\tNot reported\n\tNot reported\n\tNot reported\nAccess to medicines\t\n\tPages 55-66\n\tPages 55-66\nAffordability and pricing\t\n\tNot reported\n\tPages 55-66\n\tPages 55-66"
  },
  {
    "page": 187,
    "source": "table",
    "content": "Drug safety\n250a.1 List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts Pages 169-173\nfor Human Medical Products database FAERS MedWatch\n250a.2 Number of fatalities associated with products as reported in the FDA Adverse Event Pages 169-173\nReporting System FAERS MedWatch\n250a.3 Number of recalls issued, and total units recalled Pages 169-173\nFAERS MedWatch\n250a.4 Total amount of product accepted for takeback, reuse, or disposal Pages 113-116\n250a.5 Number of FDA enforcement actions taken in response to violations of current Not reported\nGood Manufacturing Practices (cGMP), by type\nCounterfeit drugs\n260a.1 Description of methods and technologies used to maintain traceability of products throughout Pages 169-173\nthe supply chain and prevent counterfeiting\n260a.2 Discussion of process for alerting customers and business partners of potential or known risks Pages 169-173\nassociated with counterfeit products\n260a.3 Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related Not reported\nto counterfeit products\nEthical marketing\n270a.1 Total amount of monetary losses as a result of legal proceedings associated with false Not reported\nmarketing claims\n270a.2 Description of code of ethics governing promotion of off-label use of products Pages 174-175\nEmployee recruitment, development and retention\n330a.1 Discussion of talent recruitment and retention efforts for scientists and research and Pages 125-131\ndevelopment personnel\n330a.2 Voluntary and involuntary turnover rate for: executives/senior managers, mid-level managers, Pages 125-131\nprofessionals, and all others\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t187"
  },
  {
    "page": 187,
    "source": "table",
    "content": "Drug safety\t\n\tPages 169-173\nFAERS MedWatch\n\tPages 169-173\nFAERS MedWatch\n\tPages 169-173\nFAERS MedWatch\n\tPages 113-116\n\tNot reported\nCounterfeit drugs\t\n\tPages 169-173\n\tPages 169-173\n\tNot reported\nEthical marketing\t\n\tNot reported\n\tPages 174-175\nEmployee recruitment, development and retention\t\n\tPages 125-131\n\tPages 125-131"
  },
  {
    "page": 188,
    "source": "table",
    "content": "Supply chain management\n430a.1 Percentage of entity's facilities and Tier I suppliers' facilities participating in the Rx-360 Not reported\nInternational Pharmaceutical Supply Chain Consortium audit program or equivalent third-party\naudit programs for integrity of supply chain and ingredients\nBusiness ethics\n510a.1 Total amount of monetary losses as a result of legal proceedings associated with corruption Not reported\nand bribery\n510a.2 Description of code of ethics governing interactions with health care professionals Pages 39-40\nCode of Conduct & Compliance\nActivity metrics\n000.A Number of patients treated Not reported\n000.B Number of drugs in portfolio, and in research and development (Phases 1-3) Pages 27-29\nPipeline\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t188"
  },
  {
    "page": 188,
    "source": "table",
    "content": "Supply chain management\t\n\tNot reported\nBusiness ethics\t\n\tNot reported\n\tPages 39-40\nCode of Conduct & Compliance\nActivity metrics\t\n\tNot reported\n\tPages 27-29\nPipeline"
  },
  {
    "page": 189,
    "source": "table",
    "content": "UN Global\nCompact (UNGC)\t\tThe UNGC is a strategic initiative that helps companies align their business activities and\nstrategies with ten universally recognized principles in the areas of human rights, labor standards,\nenvironmental protection and the fight against corruption. The table below summarizes how our\nexisting reporting aligns with these disclosures and where the information can be found in this\nreport, which serves as our Communication on Progress to UNGC.\t\nHuman rights\n1 Businesses should support and respect the protection of internationally proclaimed human rights Pages 161-163\n2 Businesses should make sure that they are not complicit in human rights abuses Pages 122-123, 161-166\nLabor\n3 Businesses should uphold the freedom of association and the effective recognition of the rights Pages 161-163\nto collective bargaining\n4 Businesses should support the elimination of all forms of forced and compulsory labor Pages 161-163\n5 Businesses should support the effective abolition of child labor Pages 161-163\n6 Businesses should support the elimination of discrimination in respect of employment Pages 148-161, 161-163\nand occupation\nEnvironment\n7 Businesses should support a precautionary approach to environmental challenges Pages 83-87, 93-101, 110-116\n8 Businesses should undertake initiatives to promote greater environmental responsibility Pages 83-123\n9 Businesses should encourage the development and diffusion of environmentally Pages 83-87, 93-101\nfriendly technologies\nAnti-corruption\n10 Businesses should work against corruption in all its forms, including extortion and bribery Pages 39-40, 78-81, 164-166\t\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t189"
  },
  {
    "page": 189,
    "source": "table",
    "content": "Human rights\t\n\tPages 161-163\n\tPages 122-123, 161-166\nLabor\t\n\tPages 161-163\n\tPages 161-163\n\tPages 161-163\n\tPages 148-161, 161-163\nEnvironment\t\n\tPages 83-87, 93-101, 110-116\n\tPages 83-123\n\tPages 83-87, 93-101\nAnti-corruption\t\n\tPages 39-40, 78-81, 164-166"
  },
  {
    "page": 190,
    "source": "table",
    "content": "UN Sustainable\nDevelopment Goals (\t\tSDGs)\tThe SDGs are a set of 17 global goals whose aim is to end poverty, fight\ninequality and injustice, and tackle climate change by 2030. The table\nbelow summarizes how our reporting aligns with the SDGs and where\nthis information can be found in this report. More information on our\npriorities can also be found on page 11.\t\n\tGoal Description Response\nSDG 1: No Poverty End poverty in all its forms everywhere Pages 55-74, 82\nSDG 2: Zero Hunger End hunger, achieve food security and improved nutrition and promote Merck Animal Health\nsustainable agriculture\nSDG 3: Good Health & Well-being Ensure healthy lives and promote well-being for all at all ages Pages 55-74, 131-141\nSDG 4: Quality Education Ensure inclusive and equitable quality education and promote lifelong learning Pages 142-147\nopportunities for all\nSDG 5: Gender Equality Achieve gender equality and empower all women and girls Pages 124-131, 142-161, 164-166\nSDG 6: Clean Water & Sanitation Ensure availability and sustainable management of water and sanitation for all Pages 93-101, 113-116\nSDG 7: Affordable & Clean Energy Ensure access to affordable, reliable, sustainable and modern energy for all Pages 88-92\nSDG 8: Decent Work & Economic Growth Promote sustained, inclusive and sustainable economic growth, full and productive Pages 27-30, 45-47, 52-54,\nemployment and decent work for all 88-92, 124-141, 142-161, 164-166\nSDG 9: Industry, Innovation & Infrastructure Build resilient infrastructure, promote inclusive and sustainable industrialization Pages 52-74\nand foster innovation\nSDG 10: Reduced Inequalities Reduce inequality within and among countries Pages 27-30, 124-131, 142-161\nSDG 11: Cities & Communities Make cities and human settlements inclusive, safe, resilient and sustainable Not applicable\nSDG 12: Responsible Consumption & Production Ensure sustainable consumption and production patterns Pages 83-116, 174-175\nSDG 13: Climate Action Take urgent action to combat climate change and its impacts Pages 53-54, 88-92, 104-109\nSDG 14: Life Below Water Conserve and sustainably use the oceans, seas and marine resources for Pages 35, 93-103\nsustainable development\t\t\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t\t190"
  },
  {
    "page": 190,
    "source": "table",
    "content": "Goal\tDescription\tResponse\n\t\tPages 55-74, 82\n\t\tMerck Animal Health\n\t\tPages 55-74, 131-141\n\t\tPages 142-147\n\t\tPages 124-131, 142-161, 164-166\n\t\tPages 93-101, 113-116\n\t\tPages 88-92\n\t\tPages 27-30, 45-47, 52-54,\n88-92, 124-141, 142-161, 164-166\n\t\tPages 52-74\n\t\tPages 27-30, 124-131, 142-161\n\t\tNot applicable\n\t\tPages 83-116, 174-175\n\t\tPages 53-54, 88-92, 104-109\n\t\tPages 35, 93-103"
  },
  {
    "page": 191,
    "source": "table",
    "content": "SDG 15: Life on Land Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably Pages 93-116\nmanage forests, combat desertification, and halt and reverse land degradation and\nhalt biodiversity loss\nSDG 16: Peace, Justice & Strong Institutions Promote peaceful and inclusive societies for sustainable development, provide access Pages 39-40, 41-44, 80-81,\nto justice for all and build effective, accountable and inclusive institutions at all levels 116-121, 132-141, 164-166,\n167-177\nSDG 17: Partnerships for the Goals Strengthen the means of implementation and revitalize the global partnership for Pages 35-36, 45-47, 82\nsustainable development\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t191"
  },
  {
    "page": 191,
    "source": "table",
    "content": "Pages 93-116\nPages 39-40, 41-44, 80-81,\n116-121, 132-141, 164-166,\n167-177\nPages 35-36, 45-47, 82"
  },
  {
    "page": 192,
    "source": "table",
    "content": "Culture of Health for\nBusiness (COH4B)\t\t\tThe Culture of Health for Business (COH4B) is a framework for companies to disclose\ntheir impact on health of employees, families and communities, as well as brand and\nfinancial performance, that lead to both positive and negative business outcomes.\nThe table below summarizes how our reporting aligns with the recommended metrics\nfor the Biotechnology & Pharmaceuticals Standard within the Health Care sector and\nwhere this information can be found in this report.\t\n\tStrategic\nHealth culture Promoting an organizational culture of health Pages 127-141, COVID-19\nResponsible corporate Activity that shapes public policy or public opinion Pages 36-38, 166-167,\npolitical activity Transparency Disclosures\nResponsible marketing Commitments to responsible marketing Pages 174-175\npractices\nPolicies & Benefits\nHealth promotion and wellness Providing health promotion and wellness programs Pages 124-141\nPaid family and medical leave Allowing employees to earn pay while away attending to illness, a family member or newborn Pages 124-141\nHealth insurance Providing employer-based health insurance Pages 124-141\nEquality, diversity Managing inequality, discrimination and diversity, including disability Pages 124-131, 148-163\nand impartiality\nFinancial literacy Providing financial literacy resources Pages 124-131\nWorkforce & Operations\nWork time Managing working hours, schedules and schedule control Pages 124-131\nJob security Managing job insecurity Pages 124-131\nPay practices Managing wage policies, minimum wages, wage satisfaction Pages 124-131,\nCompensation and benefits\nOccupational health and safety Mandatory and voluntary occupational health and safety Pages 131-141\nPhysical environment Managing air quality, lighting, green buildings, health promotion attempts through Pages 83-123\nthe built environment\t\t\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t\t192"
  },
  {
    "page": 192,
    "source": "table",
    "content": "Strategic\t\n\tPages 127-141, COVID-19\n\tPages 36-38, 166-167,\nTransparency Disclosures\n\tPages 174-175\nPolicies & Benefits\t\n\tPages 124-141\n\tPages 124-141\n\tPages 124-141\n\tPages 124-131, 148-163\n\tPages 124-131\nWorkforce & Operations\t\n\tPages 124-131\n\tPages 124-131\n\tPages 124-131,\nCompensation and benefits\n\tPages 131-141\n\tPages 83-123"
  },
  {
    "page": 193,
    "source": "table",
    "content": "Community\nCommunity environmental Managing the environmental impacts of company operations on communities Pages 83-123\nimpacts CDP Water Security\nCDP Climate Change\nSocial capital and cohesion Encouraging links, shared values and understanding Pages 18-20, 124-131\nCommunity involvement Investments in programs to benefit communities, including disaster response and recovery Pages 55-74, 124-131,\nPhilanthropy, Impact Investing,\nMedical Outreach Program\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t193"
  },
  {
    "page": 193,
    "source": "table",
    "content": "Community\t\n\tPages 83-123\nCDP Water Security\nCDP Climate Change\n\tPages 18-20, 124-131\n\tPages 55-74, 124-131,\nPhilanthropy, Impact Investing,\nMedical Outreach Program"
  },
  {
    "page": 194,
    "source": "table",
    "content": "Stakeholder\nCapitalism Metrics\t\tAt the 2020 Annual Meeting in Davos, 120 of the world’s largest companies supported efforts to\ndevelope a core set of common metrics and disclosures for their investors and other stakeholders.\nBelow is our alignment against the Core metrics from this framework developed by the World\nEconomic Forum, as well as select disclosures from the Expanded metrics. Merck currently is not a\nsignatory to the Stakeholder Capitalism Metrics.\t\n\tPrinciples of Governance\nGoverning Purpose\nSetting purpose (Core) Not reported\nPurpose-led management (Expanded) Overview (Pages 6-9)\nQuality of Governing Body\nGovernance body composition (Core) Pages 41-43\nProgress against strategic milestones (Expanded) Access to medicine (Pages 55-74),\nProduct quality and safety (Pages 30-34, 55-74, 78-79, 167-175, Clinical trials page),\nPublic health risks (Pages 55-74),\nEthics in R&D (Pages 39-40, 55-74, 167-173, Clincal trials page),\nEmployee health and safety (Pages 131-141),\nEmployee engagement and diversity (Pages 29, 45-47, 148-161),\nClimate change (Pages 53-54, 88-92, 104-109),\nBusiness ethics (Pages 39-40, 78-79, 174-175, Code of Conduct & Compliance),\nData privacy and security (Pages 175-177),\nGovernance structures and mechanisms (Pages 39, 41-47, 132-136, 159-161, 177)\nRemuneration (Expanded) Page 44\t\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t\t194"
  },
  {
    "page": 194,
    "source": "table",
    "content": "Principles of Governance\t\nGoverning Purpose\t\n\tNot reported\n\tOverview (Pages 6-9)\nQuality of Governing Body\t\n\tPages 41-43\n\tAccess to medicine (Pages 55-74),\nProduct quality and safety (Pages 30-34, 55-74, 78-79, 167-175, Clinical trials page),\nPublic health risks (Pages 55-74),\nEthics in R&D (Pages 39-40, 55-74, 167-173, Clincal trials page),\nEmployee health and safety (Pages 131-141),\nEmployee engagement and diversity (Pages 29, 45-47, 148-161),\nClimate change (Pages 53-54, 88-92, 104-109),\nBusiness ethics (Pages 39-40, 78-79, 174-175, Code of Conduct & Compliance),\nData privacy and security (Pages 175-177),\nGovernance structures and mechanisms (Pages 39, 41-47, 132-136, 159-161, 177)\n\tPage 44"
  },
  {
    "page": 195,
    "source": "table",
    "content": "Stakeholder Engagement\nMaterial issues impacting stakeholders (Core) Pages 45-47, 48-50\nEthical Behavior\nAnti-corruption (Core) Pages 78-79\nProtected ethics advice and reporting mechanisms (Core) Pages 39-40\nAlignment of strategy and policies to lobbying (Expanded) Pages 166-167\nRisk and Opportunity Oversight\nIntegrating risk and opportunity into business process (Core) Pages 41-43, 48-50\nPlanet\nClimate Change\nGreenhouse gas (GHG) emissions (Core) Pages 106-108\nParis-aligned GHG emissions targets (Expanded) Pages 104-109\nTCFD implementation (Core) Pages 53-54\nNature Loss\nLand use and ecological sensitivity (Core) Pages 102-103\nFreshwater Availability\nWater consumption and withdrawal in water-stressed areas (Core) Pages 93-101\nImpact of freshwater consumption and withdrawal (Expanded) CDP Water Security\nAir Pollution\nAir pollution (Expanded) Pages 108-109\nPeople\nDignity and Equality\nDiversity and inclusion (Core) Pages 159-161\nPay equality (Core) Pages 149-150\nWage level (Core) Not reported\t\t\nMerck ESG Progress Report 2021/2022\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t195"
  },
  {
    "page": 195,
    "source": "table",
    "content": "Stakeholder Engagement\t\n\tPages 45-47, 48-50\nEthical Behavior\t\n\tPages 78-79\n\tPages 39-40\n\tPages 166-167\nRisk and Opportunity Oversight\t\n\tPages 41-43, 48-50\nPlanet\t\nClimate Change\t\n\tPages 106-108\n\tPages 104-109\n\tPages 53-54\nNature Loss\t\n\tPages 102-103\nFreshwater Availability\t\n\tPages 93-101\n\tCDP Water Security\nAir Pollution\t\n\tPages 108-109\nPeople\t\nDignity and Equality\t\n\tPages 159-161\n\tPages 149-150\n\tNot reported"
  },
  {
    "page": 196,
    "source": "table",
    "content": "Risk for incidents of child, forced or compulsory labor (Core) Pages 161-163\nHuman rights review, grievance impact and modern slavery (Expanded) Pages 161-163\nFreedom of association and collective bargaining at risk (Expanded) Pages 45-47, 164-166\nHealth and Wellbeing\nHealth and safety (Core) Pages 138-141\nEmployee wellbeing (Expanded) Pages 131-141\nSkills for the Future\nTraining provided (Core) Pages 142-147\nProsperity\nEmployment and Wealth Generation\nAbsolute number and rate of employment (Core) Pages 124-131\nInfrastructure investments and services supported (Expanded) Pages 55-74\nEconomic contribution (Core) Pages 52-54\n2021 Form 10-K\nFinancial investment contribution (Core) 2021 Form 10-K\nSignificant indirect economic impacts (Expanded) Pages 55-74\nInnovation for Better Products and Services\nTotal R&D expenses (Core) 2021 Form 10-K (page 61)\nCommunity and Social Vitality\nTotal tax paid (Core) Page 82\nAdditional tax remitted (Expanded) Page 82\t\t\nMerck ESG Progress Report 2021/2022\t\tOverview GRI/SASB: General disclosures Economic Environmental Social Indices\t196"
  },
  {
    "page": 196,
    "source": "table",
    "content": "Pages 161-163\n\tPages 161-163\n\tPages 45-47, 164-166\nHealth and Wellbeing\t\n\tPages 138-141\n\tPages 131-141\nSkills for the Future\t\n\tPages 142-147\nProsperity\t\nEmployment and Wealth Generation\t\n\tPages 124-131\n\tPages 55-74\n\tPages 52-54\n2021 Form 10-K\n\t2021 Form 10-K\n\tPages 55-74\nInnovation for Better Products and Services\t\n\t2021 Form 10-K (page 61)\nCommunity and Social Vitality\t\n\tPage 82\n\tPage 82"
  }
]